beta

ABT

Abbott Laboratories

Abt

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

10-17-2018 07-18-2018 04-18-2018 01-24-2018 10-18-2017 07-20-2017 04-19-2017
Actual EPS 0.75 0.73 0.59 0.74 0.66 0.62 0.48
Consensus EPS 0.74 0.71 0.58 0.73 0.65 0.6 0.43
Estimated EPS 0.74 0.71 0.58 0.73 0.65 0.6 0.43
Number of Estimates 10 10 11 10 11 11 9
EPS Surprise $0.01 $0.02 $0.01 $0.01 $0.01 $0.02 $0.05

Stats

Summary

Abbott Laboratories is a health care company that manufactures medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs.

Market Cap: 110 Billion

Primary Exchange: New York Stock Exchange

Website: http://www.abbott.com

Shares Outstanding: 1.74 Billion

Float: 1.73 Billion

Dividend: 1.12 (1.77%)

Beta: 1.579173

Sector: Healthcare

Industry: Drug Manufacturers

Short Interest (Jan 12, 2018): 9.69 Million

Ethical Flags

Animal testing

Longest drawdown: 535 trading days

From: 2015-07-23 To: 2017-09-06

Lowest Point:

Abbott to Present at J.P. Morgan Healthcare Conference

via: PR Newswire at 2018-12-11 09:00:00:000

ABBOTT PARK, Ill., Dec. 11, 2018 /PRNewswire/ --Abbott (NYSE: ABT)will present at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019 . Brian Yoor , executive vice president of finance and Chief Financial Officer, will present at the conference at 11… read more...

Dividend Income Update November 2018

via: SeekingAlpha at 2018-12-11 06:07:16:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online as it only provides further proof that dividend invest… read more...

There Are Better Drug Stocks Than GlaxoSmithKline - Cramer's Lightning Round (12/7/18)

via: SeekingAlpha at 2018-12-10 05:59:50:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, December 7 . Bullish Call Abbott Laboratories (ABT): CEO Miles White is doing a good job and the medical device business is good. They also have a good balance sheet and Cramer's trust holds the s… read more...

Stocks To Watch: Tencent Music, Starbucks And Under Armour In Focus

via: SeekingAlpha at 2018-12-08 09:31:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are prepping for another week of volatility as concerns over the China tr… read more...

Stocks To Watch: Tencent Music, Starbucks And Under Armour In Focus

via: SeekingAlpha at 2018-12-08 09:31:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are prepping for another week of volatility as concerns over the China tr… read more...

Cramer's lightning round: There are better drug stocks to own than GlaxoSmithKline

via: CNBC at 2018-12-07 18:46:00:000

No summary available. read more...

My 34 Holding Dividend Growth Portfolio Update

via: SeekingAlpha at 2018-12-06 15:46:25:000

Introduction Welcome to my monthly portfolio review covering all of the activity over the past month. This article series covers my investing journey as a father of two towards my eventual retirement. Any specific stocks or amounts are particular to my self-directed 401( K ) plan. The goal… read more...

My 34 Holding Dividend Growth Portfolio Update

via: SeekingAlpha at 2018-12-06 15:46:25:000

Introduction Welcome to my monthly portfolio review covering all of the activity over the past month. This article series covers my investing journey as a father of two towards my eventual retirement. Any specific stocks or amounts are particular to my self-directed 401( K ) plan. The goal… read more...

March To Freedom Fund November Update

via: SeekingAlpha at 2018-12-06 10:46:52:000

We are now in the home stretch for 2018 and our portfolio has performed quite well this year. The March to Freedom Fund has a total return for the year of 9.63%. As always, this includes just share price appreciation and dividends received, but not the contributions that weve made. The… read more...

March To Freedom Fund November Update

via: SeekingAlpha at 2018-12-06 10:46:52:000

We are now in the home stretch for 2018 and our portfolio has performed quite well this year. The March to Freedom Fund has a total return for the year of 9.63%. As always, this includes just share price appreciation and dividends received, but not the contributions that weve made. The… read more...

Abbott, Graco Expected To Announce Double-Digit Increases In December

via: SeekingAlpha at 2018-12-04 10:48:09:000

Those of you who follow this series of articles know that I track the dividend increases of a variety of long-term dividend growth companies. Back at the end of October, I provided predictions for 10 dividend growth companies that have historically announced annual payout increases in November… read more...

Abbott, Graco Expected To Announce Double-Digit Increases In December

via: SeekingAlpha at 2018-12-04 10:48:09:000

Those of you who follow this series of articles know that I track the dividend increases of a variety of long-term dividend growth companies. Back at the end of October, I provided predictions for 10 dividend growth companies that have historically announced annual payout increases in November… read more...

UBS Global Wealth Management to include environmental scores on its funds in 2019

via: CNBC at 2018-12-03 07:20:00:000

No summary available. read more...

Expected Dividend Increases In December 2018

via: SeekingAlpha at 2018-12-01 13:04:00:000

Thanksgiving is over, the first major snow has hit our hometown, and look out, our Cleveland Browns have finally won back-to-back football games! Now that the calendar is set to turn and we enter the most exciting dividend month of the year, you know what that means? It is time for the next in… read more...

Expected Dividend Increases In December 2018

via: SeekingAlpha at 2018-12-01 13:04:00:000

Thanksgiving is over, the first major snow has hit our hometown, and look out, our Cleveland Browns have finally won back-to-back football games! Now that the calendar is set to turn and we enter the most exciting dividend month of the year, you know what that means? It is time for the next in… read more...

My Growth And Dividend Portfolio: What I'm Going To Add In December

via: SeekingAlpha at 2018-11-30 11:30:15:000

Introduction Over the past two years, I have spent intensively most of my spare time building out a methodology that matches my risk profile and investment horizon. But as you already know, an investment portfolio is never finished, and further improvements can always be made to reduce the r… read more...

Cramer's lightning round: Buy DowDuPont-the breakup-related pain is over

via: CNBC at 2018-11-29 18:47:00:000

No summary available. read more...

Synthorx Files Proposed Terms For U.S. IPO

via: SeekingAlpha at 2018-11-29 11:32:20:000

Quick Take Synthorx ( THOR ) intends to raise $100 million in an IPO of its common stock, per an amended registration statement . The company is advancing a pipeline of biologic treatment candidates for cancers and autoimmune diseases. THOR wont enter Phase 1 trials for its lead… read more...

FDA to reboot 501(k) process for devices

via: SeekingAlpha at 2018-11-26 10:47:03:000

Aimed at boosting efficiency in advancing new medical technologies to patients, the FDA is updating its 501(k) device approval process, a pathway for clearing low- and moderate-risk products based on demonstrating substantial equivalence to devices already on the market (called predicate d… read more...

FDA to reboot 501(k) process for devices

via: SeekingAlpha at 2018-11-26 10:47:03:000

Aimed at boosting efficiency in advancing new medical technologies to patients, the FDA is updating its 501(k) device approval process, a pathway for clearing low- and moderate-risk products based on demonstrating substantial equivalence to devices already on the market (called predicate d… read more...

FDA to reboot 501(k) process for devices

via: SeekingAlpha at 2018-11-26 10:47:03:000

Aimed at boosting efficiency in advancing new medical technologies to patients, the FDA is updating its 501(k) device approval process, a pathway for clearing low- and moderate-risk products based on demonstrating substantial equivalence to devices already on the market (called predicate d… read more...

When Retirees Leave The Investment Ring, That Sensible Portfolio Can Keep On Keeping On

via: SeekingAlpha at 2018-11-23 06:39:50:000

Think of the retiree portfolio hand-off as "from self-directed hands to no-directed hands". Those of us who self-direct our stock, or stock and ETF portfolio, might feel that everything has to be watched and massaged, and it has to be under constant scrutiny. Nothing could be further from the … read more...

When Retirees Leave The Investment Ring, That Sensible Portfolio Can Keep On Keeping On

via: SeekingAlpha at 2018-11-23 06:39:50:000

Think of the retiree portfolio hand-off as "from self-directed hands to no-directed hands". Those of us who self-direct our stock, or stock and ETF portfolio, might feel that everything has to be watched and massaged, and it has to be under constant scrutiny. Nothing could be further from the … read more...

When Retirees Leave The Investment Ring, That Sensible Portfolio Can Keep On Keeping On

via: SeekingAlpha at 2018-11-23 06:39:50:000

Think of the retiree portfolio hand-off as "from self-directed hands to no-directed hands". Those of us who self-direct our stock, or stock and ETF portfolio, might feel that everything has to be watched and massaged, and it has to be under constant scrutiny. Nothing could be further from the … read more...

How I Filter And Screen To Find The Best Stocks

via: SeekingAlpha at 2018-11-20 13:17:49:000

Introduction Most of my articles involve analysis of a company or two. I usually offer my readers an analysis of a specific company from a specific sector. Sometimes I offer a comparison between two similar companies, as I try to offer my insights about both, and which one of them is mo… read more...

How I Filter And Screen To Find The Best Stocks

via: SeekingAlpha at 2018-11-20 13:17:49:000

Introduction Most of my articles involve analysis of a company or two. I usually offer my readers an analysis of a specific company from a specific sector. Sometimes I offer a comparison between two similar companies, as I try to offer my insights about both, and which one of them is mo… read more...

DiaMedica Therapeutics Aims For $15 Million IPO

via: SeekingAlpha at 2018-11-16 10:23:50:000

Quick Take DiaMedica Therapeutics ( DMAC ) intends to raise gross proceeds of $15 million from a U.S. IPO, according to an S-1 registration statement . The firm develops synthetic proteins for the treatment of neurological and kidney diseases. DMAC achieved positive initial safety trial… read more...

DiaMedica Therapeutics Aims For $15 Million IPO

via: SeekingAlpha at 2018-11-16 10:23:50:000

Quick Take DiaMedica Therapeutics ( DMAC ) intends to raise gross proceeds of $15 million from a U.S. IPO, according to an S-1 registration statement . The firm develops synthetic proteins for the treatment of neurological and kidney diseases. DMAC achieved positive initial safety trial… read more...

DiaMedica Therapeutics Aims For $15 Million IPO

via: SeekingAlpha at 2018-11-16 10:23:50:000

Quick Take DiaMedica Therapeutics ( DMAC ) intends to raise gross proceeds of $15 million from a U.S. IPO, according to an S-1 registration statement . The firm develops synthetic proteins for the treatment of neurological and kidney diseases. DMAC achieved positive initial safety trial… read more...

DiaMedica Therapeutics Aims For $15 Million IPO

via: SeekingAlpha at 2018-11-16 10:23:50:000

Quick Take DiaMedica Therapeutics ( DMAC ) intends to raise gross proceeds of $15 million from a U.S. IPO, according to an S-1 registration statement . The firm develops synthetic proteins for the treatment of neurological and kidney diseases. DMAC achieved positive initial safety trial… read more...

Biotech Giant Should Deliver Mid-Teens Total Returns

via: SeekingAlpha at 2018-11-15 09:30:48:000

Thesis AbbVie ( ABBV ) has turned into one of the most profitable biotech companies in the world. Unlike many of its peers, AbbVie is focused on sharing its profits with investors via dividend payments. AbbVie offers a high dividend yield, generous dividend increases, and its dividend look… read more...

New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant

via: PR Newswire at 2018-11-15 09:00:00:000

ABBOTT PARK, Ill., Nov. 15, 2018 /PRNewswire/ --Abbott (NYSE: ABT) today announced the launch of the new DRG Invisible Trial System, which is approved by the U.S. Food and Drug Administration (FDA) and received CE Mark in Europe . People battling complex chronic pain conditions can … read more...

Crippling Constraints On Millennials: Asset Allocation Daily

via: SeekingAlpha at 2018-11-14 09:06:32:000

List Of 12 Worries 6. The impact of rising rates on highly leveraged corporates (especially in the US, after years of borrowing like crazy) - This concerns the inevitable hit to profits from higher interest costs and a potential major reduction in debt-funded stock buybacks. That's… read more...

Abbott Recommends Rejection of Below-Market Mini-Tender Offer by Baker Mills LLC

via: PR Newswire at 2018-11-14 09:00:00:000

ABBOTT PARK , Illinois , Nov. 14, 2018 /PRNewswire/ --Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approximately 0.003 percent of the company's outstanding shares…. read more...

SEC settles insider trading claims against former chief at Advanced Medical Optics

via: SeekingAlpha at 2018-11-13 16:20:55:000

The SEC has agreed to settle insider trading claims against James Mazzo, the former Chairman & CEO of Advanced Medical Optics. He has agreed to pay a $1.5M civil penalty and accept a five-year ban on holding officer or director positions. More news on: Abbott Laboratories, National V… read more...

Tracking Yacktman Asset Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-10 11:36:08:000

This article is part of a series that provides an ongoing analysis of the changes made to Yacktmans 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Managements regulatory 13F Form filed on 11/08/2018. Please visit our Tracking Yacktman Asset Managemen… read more...

Tracking Yacktman Asset Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-10 11:36:08:000

This article is part of a series that provides an ongoing analysis of the changes made to Yacktmans 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Managements regulatory 13F Form filed on 11/08/2018. Please visit our Tracking Yacktman Asset Managemen… read more...

Tracking Yacktman Asset Management Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-10 11:36:08:000

This article is part of a series that provides an ongoing analysis of the changes made to Yacktmans 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Managements regulatory 13F Form filed on 11/08/2018. Please visit our Tracking Yacktman Asset Managemen… read more...

My Dividend Growth Portfolio - 34 Holdings, 2 Buys, 1 Sell

via: SeekingAlpha at 2018-11-08 02:02:50:000

Introduction Welcome to my monthly portfolio review covering all of the activity over the past month. This article series covers my investing journey as a father of two towards my eventual retirement. Any specific stocks or amounts are particular to my self-directed 401(k) plan. The go… read more...

My Dividend Growth Portfolio - 34 Holdings, 2 Buys, 1 Sell

via: SeekingAlpha at 2018-11-08 02:02:50:000

Introduction Welcome to my monthly portfolio review covering all of the activity over the past month. This article series covers my investing journey as a father of two towards my eventual retirement. Any specific stocks or amounts are particular to my self-directed 401(k) plan. The go… read more...

Cramer's advice on investing during Washington gridlock: Buy fast growers

via: CNBC at 2018-11-07 18:14:00:000

No summary available. read more...

Guardion Health Sciences Begins U.S. IPO Effort

via: SeekingAlpha at 2018-11-02 17:38:41:000

Quick Take Guardion Health Sciences ( GHSI ) intends to raise gross proceeds of $10 million from a U.S. IPO, according to an S-1 registration statement . The firm provides condition-specific medical foods and vision testing solutions. GHSI is seeking public capital at a difficult time i… read more...

Guardion Health Sciences Begins U.S. IPO Effort

via: SeekingAlpha at 2018-11-02 17:38:41:000

Quick Take Guardion Health Sciences ( GHSI ) intends to raise gross proceeds of $10 million from a U.S. IPO, according to an S-1 registration statement . The firm provides condition-specific medical foods and vision testing solutions. GHSI is seeking public capital at a difficult time i… read more...

Guardion Health Sciences Begins U.S. IPO Effort

via: SeekingAlpha at 2018-11-02 17:38:41:000

Quick Take Guardion Health Sciences ( GHSI ) intends to raise gross proceeds of $10 million from a U.S. IPO, according to an S-1 registration statement . The firm provides condition-specific medical foods and vision testing solutions. GHSI is seeking public capital at a difficult time i… read more...

Guardion Health Sciences Begins U.S. IPO Effort

via: SeekingAlpha at 2018-11-02 17:38:41:000

Quick Take Guardion Health Sciences ( GHSI ) intends to raise gross proceeds of $10 million from a U.S. IPO, according to an S-1 registration statement . The firm provides condition-specific medical foods and vision testing solutions. GHSI is seeking public capital at a difficult time i… read more...

Guardion Health Sciences Begins U.S. IPO Effort

via: SeekingAlpha at 2018-11-02 17:38:41:000

Quick Take Guardion Health Sciences ( GHSI ) intends to raise gross proceeds of $10 million from a U.S. IPO, according to an S-1 registration statement . The firm provides condition-specific medical foods and vision testing solutions. GHSI is seeking public capital at a difficult time i… read more...

Poplar Forest Capital Quarterly Letter Q3 2018

via: SeekingAlpha at 2018-10-31 08:45:00:000

Read more … read more...

Poplar Forest Capital Quarterly Letter Q3 2018

via: SeekingAlpha at 2018-10-31 08:45:00:000

Read more … read more...

Abbott Laboratories' Pipeline Positioned To Produce

via: SeekingAlpha at 2018-10-31 07:30:10:000

Editor's note: Seeking Alpha is proud to welcome Nolan Thompson as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Investm… read more...

Abbott Laboratories' Pipeline Positioned To Produce

via: SeekingAlpha at 2018-10-31 07:30:10:000

Editor's note: Seeking Alpha is proud to welcome Nolan Thompson as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Investm… read more...

This Is Another Great Medical Devices Company To Consider

via: SeekingAlpha at 2018-10-29 11:33:07:000

Introduction In a previous article, I analyzed Becton, Dickinson and Company ( BDX ) and Medtronic ( MDT ). I found them to be great companies which are also dividend aristocrats. In the current article, I am going to analyze and try to see whether Abbott Laboratories ( ABT ) is a more attra… read more...

This Is Another Great Medical Devices Company To Consider

via: SeekingAlpha at 2018-10-29 11:33:07:000

Introduction In a previous article, I analyzed Becton, Dickinson and Company ( BDX ) and Medtronic ( MDT ). I found them to be great companies which are also dividend aristocrats. In the current article, I am going to analyze and try to see whether Abbott Laboratories ( ABT ) is a more attra… read more...

Abbott and AbbVie to pay $25M to settle TriCor case

via: SeekingAlpha at 2018-10-26 16:42:10:000

Reuters reports that Abbott (NYSE: ABT ) and AbbVie (NYSE: ABBV ) have agreed to pay a total of $25M to settle a whistleblower lawsuit accusing the companies of an alleged kickback scheme to doctors aimed at driving prescriptions for cholesterol med TriCor (fenofibrate) and for allegedly p… read more...

Abbott and AbbVie to pay $25M to settle TriCor case

via: SeekingAlpha at 2018-10-26 16:42:10:000

Reuters reports that Abbott (NYSE: ABT ) and AbbVie (NYSE: ABBV ) have agreed to pay a total of $25M to settle a whistleblower lawsuit accusing the companies of an alleged kickback scheme to doctors aimed at driving prescriptions for cholesterol med TriCor (fenofibrate) and for allegedly p… read more...

Abbott and AbbVie to pay $25M to settle TriCor case

via: SeekingAlpha at 2018-10-26 16:42:10:000

Reuters reports that Abbott (NYSE: ABT ) and AbbVie (NYSE: ABBV ) have agreed to pay a total of $25M to settle a whistleblower lawsuit accusing the companies of an alleged kickback scheme to doctors aimed at driving prescriptions for cholesterol med TriCor (fenofibrate) and for allegedly p… read more...

Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results

via: PR Newswire at 2018-10-25 09:00:00:000

ABBOTT PARK, Ill., Oct. 25, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has cleared its next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing 1,2 . These new assays enable the fastest-ever… read more...

Abbott: Triumph Upon Triumph

via: SeekingAlpha at 2018-10-25 06:40:49:000

Abbott ( ABT ) is a marvelous company. It has managed its way through difficulties time and again. Most recently, it responded to slowing growth with major acquisitions in 2016. Now in 2018, it has integrated these acquisitions and is set to reap the benefits of its effective strategies. I… read more...

These 10 companies are helping employees pay off their student loans

via: CNBC at 2018-10-24 10:51:00:000

No summary available. read more...

Abbott Laboratories: Great Company, But Is The Price Right?

via: SeekingAlpha at 2018-10-23 18:40:52:000

Abbott Laboratories ( ABT ) currently makes up just under 2% of our retirement portfolio. I consider the company to be a core holding due to the importance that the products make in the lives of consumers as well as the companys long track record of paying and increasing its dividend… read more...

Baby DivHut Dividend Income Portfolio Update Q3 2018

via: SeekingAlpha at 2018-10-22 06:55:41:000

With nine months of the year already behind us, it is time for me to highlight baby DivHut's quarterly dividend income/portfolio progress. Generally speaking, there is not much change in his portfolio on a month-to-month basis as fresh capital is not always available to make trades for him. … read more...

Baby DivHut Dividend Income Portfolio Update Q3 2018

via: SeekingAlpha at 2018-10-22 06:55:41:000

With nine months of the year already behind us, it is time for me to highlight baby DivHut's quarterly dividend income/portfolio progress. Generally speaking, there is not much change in his portfolio on a month-to-month basis as fresh capital is not always available to make trades for him. … read more...

A SWAN (Sleep Well At Night) Amid The Swoon?

via: SeekingAlpha at 2018-10-20 09:00:00:000

DGI (Dividend Growth Investing) generally means that you invest in a set of dividend-paying stocks that grow their dividend payout year after year. If you are still in the accumulation phase, reinvest (drip) the dividends, which results in more shares and higher future income. With each passin… read more...

A SWAN (Sleep Well At Night) Amid The Swoon?

via: SeekingAlpha at 2018-10-20 09:00:00:000

DGI (Dividend Growth Investing) generally means that you invest in a set of dividend-paying stocks that grow their dividend payout year after year. If you are still in the accumulation phase, reinvest (drip) the dividends, which results in more shares and higher future income. With each passin… read more...

Abbott's HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for a Heart Transplant

via: PR Newswire at 2018-10-19 09:00:00:000

ABBOTT PARK, Ill., Oct. 19, 2018 /PRNewswire/ --Abbott (NYSE: ABT) announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failu… read more...

2018 Third Quarter Review - Buying Dividend Growth Stocks Without Looking

via: SeekingAlpha at 2018-10-18 17:51:40:000

In 2015, I did what many professional fund managers will do - I just bought enough of 'em to skim or replicate an index. Now a mutual fund manager will charge some high fees for that skimming effort, I simply wanted to create the potential of greater outperformance through a market correction…. read more...

Markets Under Pressure Over Future Fed Hikes (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-10-18 07:57:37:000

Today's Top Stories: Markets under pressure on future Fed hikes; May hints at Brexit delay; and Facebook shareholders move to oust Zuckerberg. Click play to listen in your browser. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the fol… read more...

Wall Street Breakfast: Fed Maintains Hawkish Tone

via: SeekingAlpha at 2018-10-18 07:01:02:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). U.S. stock index futures are under pressure again as investors digest minutes from the Fed's most recent meeting t… read more...

Abbott Laboratories 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-10-17 14:27:08:000

The following slide deck was published by Abbott Laboratories in conjunction with their 2018 Q3 earnings Read more … read more...

Abbott Laboratories (ABT) CEO Miles White on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-17 14:20:45:000

Abbott Laboratories (ABT) Q3 2018 Results Earnings Conference Call October 17, 2018 09:00 AM ET Executives Scott Leinenweber - Vice President, Investor Relations, Licensing and Acquisitions Miles White - Chairman and Chief Executive Officer Brian Yoor - Executive Vice President,… read more...

New Study Shows Abbott's Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care

via: PR Newswire at 2018-10-17 12:44:00:000

ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ --For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology , found a new blood test under deve… read more...

Buy MedTech names due to improving fundamentals, Barclays says in sector initiation

via: CNBC at 2018-10-17 09:08:00:000

No summary available. read more...

Abbott Laboratories Q3 revenues up 12%; non-GAAP EPS up 14%; narrows guidance

via: SeekingAlpha at 2018-10-17 08:08:37:000

Abbott Laboratories ( ABT ) Q3 results: Revenues: $7,656M (+12.1%); Nutrition: $1,838M (+4.0%); Diagnostics: $1,824M (+42.6%); Established Pharmaceuticals: $1,159M; Medical Devices: $2,815M (+8.4%). More news on: Abbott Laboratories, Healthcare stocks news, Earnings news and commentary, … read more...

Abbott Laboratories EPS in-line, beats on revenue

via: SeekingAlpha at 2018-10-17 07:48:05:000

Abbott Laboratories (NYSE: ABT ): Q3 Non-GAAP EPS of $0.75 in-line; GAAP EPS of $0.31 misses by $0.03 . More news on: Abbott Laboratories, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

Abbott Reports Third-Quarter 2018 Results

via: PR Newswire at 2018-10-17 07:45:00:000

ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ -- Abbott(NYSE: ABT)today announced financial results for the third quarter ended Sept. 30, 2018 . Third-quarter worldwide sales of $7.7 billion increased 12.1 percent on a reported basis and 7.8 percent on an organic* basis. … read more...

History says the market sell-off isn't over and this drop will be 'sharper than the first'

via: CNBC at 2018-10-17 07:30:00:000

No summary available. read more...

Dow falls in volatile session after Fed hints at more rate hikes ahead

via: CNBC at 2018-10-17 04:32:00:000

No summary available. read more...

Notable earnings before Wednesday's open

via: SeekingAlpha at 2018-10-16 17:30:37:000

ABT , ASML , BMI , MTB , MTG , NTRS , UNF , USB , WGO For Seeking Alpha's full earnings season calendar, click here . More news on: Abbott Laboratories, ASML Holding N.V., Badger Meter, Inc., Earnings news and commentary, , read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-16 07:49:45:000

Abbott (NYSE: ABT ) initiated with Overweight rating and $80 (16% upside) price target at Barclays. More news on: Abbott Laboratories, Arbutus Biopharma Corp, Avanos Medical, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Abbott Names Robert B. Ford President, Chief Operating Officer

via: PR Newswire at 2018-10-15 08:30:00:000

ABBOTT PARK, Ill., Oct. 15, 2018 /PRNewswire/ --Abbott (NYSE: ABT)announced today that Robert B. Ford has been named president and chief operating officer, effective immediately. Mr. Ford, a 22-year Abbott veteran, was most recently executive vice president of Medical Devices… read more...

Game Plan For The Week - Cramer's Mad Money (10/12/18)

via: SeekingAlpha at 2018-10-15 07:38:41:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday , October 12. After the selling in the week, there could be buying in the coming week thanks to earnings and the focus shifting on outlook for companies and not macro news. "But, listen, we won't ge… read more...

Stocks To Watch: Was That A Speed Bump?

via: SeekingAlpha at 2018-10-13 09:45:24:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. That escalated quickly. While we gave a gentle reminder last week that interest rat… read more...

Stocks To Watch: Was That A Speed Bump?

via: SeekingAlpha at 2018-10-13 09:45:24:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. That escalated quickly. While we gave a gentle reminder last week that interest rat… read more...

DGHM Enhanced Value LP Monthly Commentary

via: SeekingAlpha at 2018-10-13 00:48:00:000

Read more … read more...

DGHM Enhanced Value LP Monthly Commentary

via: SeekingAlpha at 2018-10-13 00:48:00:000

Read more … read more...

Earnings could be what turns the tide for stocks

via: CNBC at 2018-10-12 18:59:00:000

No summary available. read more...

Cramer's game plan: Increased volatility could turn positive with help from Trump, Fed

via: CNBC at 2018-10-12 18:11:00:000

No summary available. read more...

My Dividend Growth Portfolio - Q3 2018 Summary

via: SeekingAlpha at 2018-10-07 14:02:42:000

Introduction It's time to summarize another quarter. This quarter was another mediocre quarter for me. I have been lagging the S&P 500 this entire year, and this quarter was no different. The total return in Q3 was 1.2% lower than the S&P 500. While it's not my ultimate benchmark, I … read more...

My Dividend Growth Portfolio - Q3 2018 Summary

via: SeekingAlpha at 2018-10-07 14:02:42:000

Introduction It's time to summarize another quarter. This quarter was another mediocre quarter for me. I have been lagging the S&P 500 this entire year, and this quarter was no different. The total return in Q3 was 1.2% lower than the S&P 500. While it's not my ultimate benchmark, I … read more...

My Dividend Growth Portfolio - Q3 2018 Summary

via: SeekingAlpha at 2018-10-07 14:02:42:000

Introduction It's time to summarize another quarter. This quarter was another mediocre quarter for me. I have been lagging the S&P 500 this entire year, and this quarter was no different. The total return in Q3 was 1.2% lower than the S&P 500. While it's not my ultimate benchmark, I … read more...

PII Dividend Growth Portfolio - 66 Holdings

via: SeekingAlpha at 2018-10-05 14:33:11:000

Editor's note: Seeking Alpha is proud to welcome Passive Income Investor as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more T… read more...

PII Dividend Growth Portfolio - 66 Holdings

via: SeekingAlpha at 2018-10-05 14:33:11:000

Editor's note: Seeking Alpha is proud to welcome Passive Income Investor as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more T… read more...

My Dividend Growth Portfolio - 35 Holdings, 6 Sells, 2 Buys

via: SeekingAlpha at 2018-10-04 03:36:49:000

What's New? After a calm August, the investment pendulum swung back to an active September. At a high level I have continued to pivot my portfolio more towards growth. In the transaction section I will highlight what has changed and why it did. Some slower growing dividend names have been cu… read more...

Abbott's next-gen FreeStyle Libre CGM CE Mark'd

via: SeekingAlpha at 2018-10-01 11:52:54:000

Abbott ( ABT +0.8% ) announces that its next-generation FreeStyle Libre 2 continuous glucose monitoring (CGM) system is now CE Mark certified. The device includes alarms to alert the user when blood sugar levels are out of range and an alarm if the sensor loses communication with the rea… read more...

Abbott's next-gen FreeStyle Libre CGM CE Mark'd

via: SeekingAlpha at 2018-10-01 11:52:54:000

Abbott ( ABT +0.8% ) announces that its next-generation FreeStyle Libre 2 continuous glucose monitoring (CGM) system is now CE Mark certified. The device includes alarms to alert the user when blood sugar levels are out of range and an alarm if the sensor loses communication with the rea… read more...

Abbott's next-gen FreeStyle Libre CGM CE Mark'd

via: SeekingAlpha at 2018-10-01 11:52:54:000

Abbott ( ABT +0.8% ) announces that its next-generation FreeStyle Libre 2 continuous glucose monitoring (CGM) system is now CE Mark certified. The device includes alarms to alert the user when blood sugar levels are out of range and an alarm if the sensor loses communication with the rea… read more...

Abbott's FreeStyle® Libre 2, with Optional Real-Time Alarms, Secures CE Mark for Use in Europe

via: PR Newswire at 2018-10-01 08:00:00:000

ABBOTT PARK, Ill., Oct. 1, 2018 /PRNewswire/ --People living with diabetes in Europe will now have the choice to be alerted in real-time of hypoglycemia (low glucose levels 1 ) or hyperglycemia (high glucose levels 1 ) through the FreeStyle Libre 2 system, a continuous gluc… read more...

Abbott's FreeStyle® Libre 2, with Optional Real-Time Alarms, Secures CE Mark for Use in Europe

via: PR Newswire at 2018-10-01 08:00:00:000

ABBOTT PARK, Ill., Oct. 1, 2018 /PRNewswire/ --People living with diabetes in Europe will now have the choice to be alerted in real-time of hypoglycemia (low glucose levels 1 ) or hyperglycemia (high glucose levels 1 ) through the FreeStyle Libre 2 system, a continuous gluc… read more...

Abbott's FreeStyle® Libre 2, with Optional Real-Time Alarms, Secures CE Mark for Use in Europe

via: PR Newswire at 2018-10-01 08:00:00:000

ABBOTT PARK, Ill., Oct. 1, 2018 /PRNewswire/ --People living with diabetes in Europe will now have the choice to be alerted in real-time of hypoglycemia (low glucose levels 1 ) or hyperglycemia (high glucose levels 1 ) through the FreeStyle Libre 2 system, a continuous gluc… read more...

Abbott's test for heart attack risk CE Mark'd

via: SeekingAlpha at 2018-09-26 21:13:35:000

Abbott (NYSE: ABT ) announces that its High Sensitive Troponin-I blood test, used to predict the risk of a heart attack months or years in advance in otherwise healthy people, is now CE Mark certified. More news on: Abbott Laboratories, Healthcare stocks news, Read more … read more...

Abbott's test for heart attack risk CE Mark'd

via: SeekingAlpha at 2018-09-26 21:13:35:000

Abbott (NYSE: ABT ) announces that its High Sensitive Troponin-I blood test, used to predict the risk of a heart attack months or years in advance in otherwise healthy people, is now CE Mark certified. More news on: Abbott Laboratories, Healthcare stocks news, Read more … read more...

Abbott's test for heart attack risk CE Mark'd

via: SeekingAlpha at 2018-09-26 21:13:35:000

Abbott (NYSE: ABT ) announces that its High Sensitive Troponin-I blood test, used to predict the risk of a heart attack months or years in advance in otherwise healthy people, is now CE Mark certified. More news on: Abbott Laboratories, Healthcare stocks news, Read more … read more...

Abbott Receives CE Mark for First Troponin Test to Help Predict the Chance of Heart Attack in Apparently Healthy Adults Potentially Months to Years in Advance

via: PR Newswire at 2018-09-26 18:01:00:000

ABBOTT PARK, Ill., Sept. 26, 2018 /PRNewswire/ --Cardiovascular diseases are the leading cause of death globally. 1 Yet unlike other conditions, heart disease can be prevented if identified early and managed through lifestyle changes and medication as needed. To help people ta… read more...

One-Year Results from Real-World Study Showed Abbott's Portico(TM) Transcatheter Aortic Valve Safely and Successfully Reduced Severe Aortic Stenosis

via: PR Newswire at 2018-09-25 14:45:00:000

SAN DIEGO , Sept. 25, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced one-year results from a real-world, international, multicenter, 941-patient study of the company's Portico transcatheter aortic valve replacement (TAVR) system in patients with symptomatic, severe aortic… read more...

Dexcom Investors Are Whistling Past The Graveyard

via: SeekingAlpha at 2018-09-25 05:00:00:000

Introduction I want to start by saying that Dexcom ( DXCM ) is not alone in the neighborhood of companies whose market capitalizations have exceeded their market size. A number of small and mid capitalization stocks in the healthcare devices, diagnostics and services sectors have run years a… read more...

Abbott: MitraClip Success Provides Upside For Stock

via: SeekingAlpha at 2018-09-24 13:24:21:000

Success on COAPT Results On Sunday, September 23, Abbott Laboratories ( ABT ) presented results from its trial entitled COAPT , for Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy. It tested the MitraClip device on functional mitral valve regurgitation, or FMR. As … read more...

Cardiac device makers in the green on positive data at industry conference

via: SeekingAlpha at 2018-09-24 11:41:03:000

Medical device makers operating in the cardiology space are seeing a spike in buying, stoked by the release of positive trial data from several participants at the Transcatheter Therapeutics Conference in San Diego. More news on: Abbott Laboratories, Edwards Lifesciences Corp, Medtronic pl… read more...

Landmark Study Shows Treatment with Abbott's MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation

via: PR Newswire at 2018-09-23 13:20:00:000

SAN DIEGO , Sept. 23, 2018 /PRNewswire/ --Abbott (NYSE: ABT) today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip device to guideline-directed medical therapy in select patients with secondary (or functiona… read more...

Gritstone Oncology Prepares Final Terms For IPO

via: SeekingAlpha at 2018-09-21 12:36:25:000

Quick Take Gritstone Oncology ( GRTS ) intends to raise $85 million in an IPO of its common stock, according to an amended registration statement . The company is developing a pipeline of cancer treatments that utilize its AI technologies to better target treatment to each patient&#x201… read more...

Gritstone Oncology Prepares Final Terms For IPO

via: SeekingAlpha at 2018-09-21 12:36:25:000

Quick Take Gritstone Oncology ( GRTS ) intends to raise $85 million in an IPO of its common stock, according to an amended registration statement . The company is developing a pipeline of cancer treatments that utilize its AI technologies to better target treatment to each patient&#x201… read more...

Abbott Hosts Conference Call for Third-Quarter Earnings

via: PR Newswire at 2018-09-19 09:00:00:000

ABBOTT PARK, Ill., Sept. 19, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2018 financial results on Wednesday, Oct. 17, 2018 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centra… read more...

Abbott Hosts Conference Call for Third-Quarter Earnings

via: PR Newswire at 2018-09-19 09:00:00:000

ABBOTT PARK, Ill., Sept. 19, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2018 financial results on Wednesday, Oct. 17, 2018 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Centra… read more...

Sonos Is Inconsistent - Cramer's Lightning Round (9/17/18)

via: SeekingAlpha at 2018-09-18 07:07:01:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, September 17 . Bullish Calls PayPal (PYPL): It has dropped 5 points. Let the stock come down by another 2 points and it will be in oversold territory. That will be the time to buy. IDEXX Laborat… read more...

Cramer Remix: A pullback in these stocks is a gift to investors

via: CNBC at 2018-09-17 18:59:00:000

No summary available. read more...

Cramer's lightning round: I prefer the stock of Wendy's to McDonald's

via: CNBC at 2018-09-17 18:49:00:000

No summary available. read more...

How To Achieve Financial 'Alpha', And My Personal Holdings

via: SeekingAlpha at 2018-09-17 15:13:51:000

The road to building wealth isn't set in stone. There is no black and white, or right and wrong. Individuals have different goals, circumstances, and means to achieve their personalized definition of financial independence, or "alpha". But the most important thing, is that you have a plan, and… read more...

FDA OKs Biotronik device for coronary artery perforations

via: SeekingAlpha at 2018-09-14 12:37:13:000

The FDA approves German device maker Biotronik's PK Papyrus Covered Coronary Stent System for the treatment of acute coronary artery perforations, a complication of heart vessel procedures like PCI. More news on: Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, Healthca… read more...

FDA OKs Biotronik device for coronary artery perforations

via: SeekingAlpha at 2018-09-14 12:37:13:000

The FDA approves German device maker Biotronik's PK Papyrus Covered Coronary Stent System for the treatment of acute coronary artery perforations, a complication of heart vessel procedures like PCI. More news on: Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, Healthca… read more...

FDA OKs Biotronik device for coronary artery perforations

via: SeekingAlpha at 2018-09-14 12:37:13:000

The FDA approves German device maker Biotronik's PK Papyrus Covered Coronary Stent System for the treatment of acute coronary artery perforations, a complication of heart vessel procedures like PCI. More news on: Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, Healthca… read more...

Abbott's MITRA-FR Potentially Not As Negative As It Appears For Upcoming COAPT Results

via: SeekingAlpha at 2018-09-13 16:47:43:000

Strong Broad-Based Growth; Recent Discussion Focused on MitraClip Abbott Laboratories ( ABT ) is a diversified healthcare conglomerate with revenue coming from Medical Devices, Nutrition, Diagnostics, and Established Pharma (generic pharmaceuticals). The stock has performed well as its segme… read more...

Abbott Laboratories declares $0.28 dividend

via: SeekingAlpha at 2018-09-13 11:54:58:000

Abbott Laboratories (NYSE: ABT ) declares $0.28/share quarterly dividend , in line with previous. Forward yield 1.66% Payable Nov. 15; for shareholders of record Oct. 15; ex-div Oct. 12. See ABT Dividend Scorecard, Yield Chart, & Dividend Growth. More news on: Abbott Labora… read more...

Abbott Declares 379th Consecutive Quarterly Dividend

via: PR Newswire at 2018-09-13 11:14:00:000

ABBOTT PARK, Ill., Sept. 13, 2018 /PRNewswire/ --The board of directors of Abbott (NYSE: ABT)today declared a quarterly common dividend of 28 centsper share. This marks the 379 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is pay… read more...

Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)

via: PR Newswire at 2018-09-13 10:58:00:000

ABBOTT PARK, Ill., Sept. 13, 2018 /PRNewswire/ --For the sixth consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and responsi… read more...

India bans 328 combo drugs, Abbott appeals

via: SeekingAlpha at 2018-09-13 10:39:15:000

Abbott's ( ABT +1% ) India unit has filed appeals in response to the Indian government's ban of 328 combination drugs citing the lack of "therapeutic justification" for the ingredients that may be risky for patients. More news on: Abbott Laboratories, Healthcare stocks news, Read mor… read more...

My Dividend Growth Portfolio - 38 Holdings, 1 Buy, 1 Sale

via: SeekingAlpha at 2018-09-07 11:56:24:000

What's New? After having an incredibly busy investment month in July, August was a little tamer. If you didn't read it, I encourage you to check out my July article . In that article, I highlighted my rationale for pivoting more towards dividend growth. I removed some holdings that while wo… read more...

My Dividend Growth Portfolio - 38 Holdings, 1 Buy, 1 Sale

via: SeekingAlpha at 2018-09-07 11:56:24:000

What's New? After having an incredibly busy investment month in July, August was a little tamer. If you didn't read it, I encourage you to check out my July article . In that article, I highlighted my rationale for pivoting more towards dividend growth. I removed some holdings that while wo… read more...

My Dividend Growth Portfolio - 38 Holdings, 1 Buy, 1 Sale

via: SeekingAlpha at 2018-09-07 11:56:24:000

What's New? After having an incredibly busy investment month in July, August was a little tamer. If you didn't read it, I encourage you to check out my July article . In that article, I highlighted my rationale for pivoting more towards dividend growth. I removed some holdings that while wo… read more...

My Dividend Growth Portfolio - 38 Holdings, 1 Buy, 1 Sale

via: SeekingAlpha at 2018-09-07 11:56:24:000

What's New? After having an incredibly busy investment month in July, August was a little tamer. If you didn't read it, I encourage you to check out my July article . In that article, I highlighted my rationale for pivoting more towards dividend growth. I removed some holdings that while wo… read more...

My Dividend Growth Portfolio - 38 Holdings, 1 Buy, 1 Sale

via: SeekingAlpha at 2018-09-07 11:56:24:000

What's New? After having an incredibly busy investment month in July, August was a little tamer. If you didn't read it, I encourage you to check out my July article . In that article, I highlighted my rationale for pivoting more towards dividend growth. I removed some holdings that while wo… read more...

Tech Is Defenseless - Cramer's Mad Money (9/6/18)

via: SeekingAlpha at 2018-09-07 07:36:22:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , September 6. The selloff in tech continued on Wednesday and everyone is looking for a reason. "Is it a slowdown in demand for digitization? Is it regulation cutting into growth? Is it a change i… read more...

Tech Is Defenseless - Cramer's Mad Money (9/6/18)

via: SeekingAlpha at 2018-09-07 07:36:22:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , September 6. The selloff in tech continued on Wednesday and everyone is looking for a reason. "Is it a slowdown in demand for digitization? Is it regulation cutting into growth? Is it a change i… read more...

Tech Is Defenseless - Cramer's Mad Money (9/6/18)

via: SeekingAlpha at 2018-09-07 07:36:22:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , September 6. The selloff in tech continued on Wednesday and everyone is looking for a reason. "Is it a slowdown in demand for digitization? Is it regulation cutting into growth? Is it a change i… read more...

Tech Is Defenseless - Cramer's Mad Money (9/6/18)

via: SeekingAlpha at 2018-09-07 07:36:22:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , September 6. The selloff in tech continued on Wednesday and everyone is looking for a reason. "Is it a slowdown in demand for digitization? Is it regulation cutting into growth? Is it a change i… read more...

Tech Is Defenseless - Cramer's Mad Money (9/6/18)

via: SeekingAlpha at 2018-09-07 07:36:22:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , September 6. The selloff in tech continued on Wednesday and everyone is looking for a reason. "Is it a slowdown in demand for digitization? Is it regulation cutting into growth? Is it a change i… read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

March To Freedom Fund: Adding Lockheed Martin

via: SeekingAlpha at 2018-09-04 09:14:48:000

The calendar has flipped to September, so it's time to look back at how the March to Freed Fund performed during the month of August. Including dividends, our total return for 2018 is 8.98%. This trails the performance of the S&P 500, which has a total return of 9.94% for the year. After… read more...

March To Freedom Fund: Adding Lockheed Martin

via: SeekingAlpha at 2018-09-04 09:14:48:000

The calendar has flipped to September, so it's time to look back at how the March to Freed Fund performed during the month of August. Including dividends, our total return for 2018 is 8.98%. This trails the performance of the S&P 500, which has a total return of 9.94% for the year. After… read more...

March To Freedom Fund: Adding Lockheed Martin

via: SeekingAlpha at 2018-09-04 09:14:48:000

The calendar has flipped to September, so it's time to look back at how the March to Freed Fund performed during the month of August. Including dividends, our total return for 2018 is 8.98%. This trails the performance of the S&P 500, which has a total return of 9.94% for the year. After… read more...

New Coverage Decision Extends Abbott's Innovative Pain Therapy Option to 22 Million Americans Living with Chronic Pain

via: PR Newswire at 2018-09-04 09:00:00:000

ABBOTT PARK, Ill., Sept. 4, 2018 /PRNewswire/ -- Abbott (NYSE: ABT)today announced a new national coverage determination for the company's dorsal root ganglion (DRG) neurostimulation pain therapy through Aetna , a leading health benefits company in the United States . With th… read more...

New Coverage Decision Extends Abbott's Innovative Pain Therapy Option to 22 Million Americans Living with Chronic Pain

via: PR Newswire at 2018-09-04 09:00:00:000

ABBOTT PARK, Ill., Sept. 4, 2018 /PRNewswire/ -- Abbott (NYSE: ABT)today announced a new national coverage determination for the company's dorsal root ganglion (DRG) neurostimulation pain therapy through Aetna , a leading health benefits company in the United States . With th… read more...

New Coverage Decision Extends Abbott's Innovative Pain Therapy Option to 22 Million Americans Living with Chronic Pain

via: PR Newswire at 2018-09-04 09:00:00:000

ABBOTT PARK, Ill., Sept. 4, 2018 /PRNewswire/ -- Abbott (NYSE: ABT)today announced a new national coverage determination for the company's dorsal root ganglion (DRG) neurostimulation pain therapy through Aetna , a leading health benefits company in the United States . With th… read more...

AbbVie: FCF's Ensure Sweet Dividends And Buybacks

via: SeekingAlpha at 2018-08-30 10:51:12:000

Article thesis AbbVie ( ABBV ) is an appealing investment for dividend seekers, as it offers a FCF yield of 8.6% based on a FCF of 13.1B USD this year and the current market cap of 152B USD. The company will produce excess cash flow, which will give investors compelling total returns over th… read more...

AbbVie: FCF's Ensure Sweet Dividends And Buybacks

via: SeekingAlpha at 2018-08-30 10:51:12:000

Article thesis AbbVie ( ABBV ) is an appealing investment for dividend seekers, as it offers a FCF yield of 8.6% based on a FCF of 13.1B USD this year and the current market cap of 152B USD. The company will produce excess cash flow, which will give investors compelling total returns over th… read more...

AbbVie: FCF's Ensure Sweet Dividends And Buybacks

via: SeekingAlpha at 2018-08-30 10:51:12:000

Article thesis AbbVie ( ABBV ) is an appealing investment for dividend seekers, as it offers a FCF yield of 8.6% based on a FCF of 13.1B USD this year and the current market cap of 152B USD. The company will produce excess cash flow, which will give investors compelling total returns over th… read more...

Dividend Aristocrats Vs Non Dividend Aristocrats.

via: SeekingAlpha at 2018-08-27 15:35:14:000

In March of 2015 I skimmed 15 of the largest cap Dividend Achievers ( VIG ). Here's my first article on that real life exercise Buying Dividend Growth Stocks Without Looking . Now certainly I did not look, that is to say I did no further evaluation of the individual companies. But the inde… read more...

Dividend Aristocrats Vs Non Dividend Aristocrats.

via: SeekingAlpha at 2018-08-27 15:35:14:000

In March of 2015 I skimmed 15 of the largest cap Dividend Achievers ( VIG ). Here's my first article on that real life exercise Buying Dividend Growth Stocks Without Looking . Now certainly I did not look, that is to say I did no further evaluation of the individual companies. But the inde… read more...

Dividend Aristocrats Vs Non Dividend Aristocrats.

via: SeekingAlpha at 2018-08-27 15:35:14:000

In March of 2015 I skimmed 15 of the largest cap Dividend Achievers ( VIG ). Here's my first article on that real life exercise Buying Dividend Growth Stocks Without Looking . Now certainly I did not look, that is to say I did no further evaluation of the individual companies. But the inde… read more...

Dexcom Acquires TypeZero Technologies For Diabetes Management Tech

via: SeekingAlpha at 2018-08-27 14:25:34:000

Quick Take Dexcom ( DXCM ) announced it has acquired TypeZero Technologies for an undisclosed amount. TypeZero Technologies provides diabetes management software for patients and clinicians. DXCM plans to launch an automated insulin delivery system based on TypeZeros inCont… read more...

Dexcom Acquires TypeZero Technologies For Diabetes Management Tech

via: SeekingAlpha at 2018-08-27 14:25:34:000

Quick Take Dexcom ( DXCM ) announced it has acquired TypeZero Technologies for an undisclosed amount. TypeZero Technologies provides diabetes management software for patients and clinicians. DXCM plans to launch an automated insulin delivery system based on TypeZeros inCont… read more...

Dexcom Acquires TypeZero Technologies For Diabetes Management Tech

via: SeekingAlpha at 2018-08-27 14:25:34:000

Quick Take Dexcom ( DXCM ) announced it has acquired TypeZero Technologies for an undisclosed amount. TypeZero Technologies provides diabetes management software for patients and clinicians. DXCM plans to launch an automated insulin delivery system based on TypeZeros inCont… read more...

Corvia Medical's interatrial shunt shows positive effect in heart failure patients

via: SeekingAlpha at 2018-08-27 13:40:32:000

One-year follow-up data on privately held Corvia Medical's transcatheter InterAtrial Shunt Device (IASD) in heart failure patients showed a sustained benefit. The results, following the successful outcome of its REDUCE LAP-HF study, were presented at the ESC Congress in Munich. More ne… read more...

Corvia Medical's interatrial shunt shows positive effect in heart failure patients

via: SeekingAlpha at 2018-08-27 13:40:32:000

One-year follow-up data on privately held Corvia Medical's transcatheter InterAtrial Shunt Device (IASD) in heart failure patients showed a sustained benefit. The results, following the successful outcome of its REDUCE LAP-HF study, were presented at the ESC Congress in Munich. More ne… read more...

Corvia Medical's interatrial shunt shows positive effect in heart failure patients

via: SeekingAlpha at 2018-08-27 13:40:32:000

One-year follow-up data on privately held Corvia Medical's transcatheter InterAtrial Shunt Device (IASD) in heart failure patients showed a sustained benefit. The results, following the successful outcome of its REDUCE LAP-HF study, were presented at the ESC Congress in Munich. More ne… read more...

Gritstone Oncology Files For $80 Million U.S. IPO

via: SeekingAlpha at 2018-08-24 11:45:07:000

Quick Take Gritstone Oncology ( GRTS ) intends to raise gross proceeds of $80 million from a U.S. IPO, according to an S-1 registration statement . The firm provides personalized immunotherapy treatments for cancer patients. GRTS has an interesting approach but hasnt entered t… read more...

Gritstone Oncology Files For $80 Million U.S. IPO

via: SeekingAlpha at 2018-08-24 11:45:07:000

Quick Take Gritstone Oncology ( GRTS ) intends to raise gross proceeds of $80 million from a U.S. IPO, according to an S-1 registration statement . The firm provides personalized immunotherapy treatments for cancer patients. GRTS has an interesting approach but hasnt entered t… read more...

Gritstone Oncology Files For $80 Million U.S. IPO

via: SeekingAlpha at 2018-08-24 11:45:07:000

Quick Take Gritstone Oncology ( GRTS ) intends to raise gross proceeds of $80 million from a U.S. IPO, according to an S-1 registration statement . The firm provides personalized immunotherapy treatments for cancer patients. GRTS has an interesting approach but hasnt entered t… read more...

RetirementRx's Mid-Year Review

via: SeekingAlpha at 2018-08-22 13:03:12:000

Introduction I am a dividend growth investor. My focus is on generating a dividend income to facilitate a smooth transition into retirement. I actively manage a real-life dividend growth portfolio called RetirementRx . RetirementRx, a plan and portfolio, was started in 2013 with a target … read more...

RetirementRx's Mid-Year Review

via: SeekingAlpha at 2018-08-22 13:03:12:000

Introduction I am a dividend growth investor. My focus is on generating a dividend income to facilitate a smooth transition into retirement. I actively manage a real-life dividend growth portfolio called RetirementRx . RetirementRx, a plan and portfolio, was started in 2013 with a target … read more...

March To Freedom Fund: July Update

via: SeekingAlpha at 2018-08-19 22:36:04:000

The March to Freedom Fund, which will provide the dividends that pay my wife's and my expenses in retirement, has spent much of the last year or so trailing the S&P 500 ( SPY ). That is something that I am fine with for two reasons: 1) In previous years weve outperformed the index … read more...

March To Freedom Fund: July Update

via: SeekingAlpha at 2018-08-19 22:36:04:000

The March to Freedom Fund, which will provide the dividends that pay my wife's and my expenses in retirement, has spent much of the last year or so trailing the S&P 500 ( SPY ). That is something that I am fine with for two reasons: 1) In previous years weve outperformed the index … read more...

Homemade Apple Dividends Are 100 Times Bigger Than The 'Real' Dividends

via: SeekingAlpha at 2018-08-18 08:10:01:000

I opened up my brokerage account today (August 17) to see that an Apple ( AAPL ) dividend had just arrived. Thanks for that, I'll take it. I'll take it even though it's just a scrap. That 'real' cash dividend is not going to take me very far. And speaking of Apple dividends taking us places, m… read more...

Homemade Apple Dividends Are 100 Times Bigger Than The 'Real' Dividends

via: SeekingAlpha at 2018-08-18 08:10:01:000

I opened up my brokerage account today (August 17) to see that an Apple ( AAPL ) dividend had just arrived. Thanks for that, I'll take it. I'll take it even though it's just a scrap. That 'real' cash dividend is not going to take me very far. And speaking of Apple dividends taking us places, m… read more...

FDA OKs brain stimulator for obsessive compulsive disorder

via: SeekingAlpha at 2018-08-17 10:05:57:000

The FDA approves Israeli device marker Brainways Ltd 's Deep Transcranial Magnetic Stimulation (TMS) System for the treatment of obsessive compulsive disorder. More news on: Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Healthcare stocks news, Read more … read more...

FDA streamlines voluntary device malfunction reporting

via: SeekingAlpha at 2018-08-16 10:22:56:000

The FDA has finalized its program for device makers for the voluntary reporting of device malfunctions. Manufacturers will be allowed to report certain product glitches on a quarterly basis and in summary form for certain product codes, reducing the number of required reports by about two … read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Buy High Quality Stocks On Turkey-Induced Weakness - Cramer's Mad Money (8/13/18)

via: SeekingAlpha at 2018-08-14 07:27:14:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday , August 13. It's as if the market did not already fear trade and tariffs, they have to worry about Turkey as well. Cramer thinks the Turkey currency crisis induced selloff is a buying opportunity… read more...

Cramer's lightning round: Coal may be in a renaissance, but don't buy the stocks

via: CNBC at 2018-08-09 18:50:00:000

No summary available. read more...

Cramer's lightning round: Coal may be in a renaissance, but don't buy the stocks

via: CNBC at 2018-08-09 18:50:00:000

No summary available. read more...

Cramer's lightning round: Coal may be in a renaissance, but don't buy the stocks

via: CNBC at 2018-08-09 18:50:00:000

No summary available. read more...

Cramer's lightning round: Coal may be in a renaissance, but don't buy the stocks

via: CNBC at 2018-08-09 18:50:00:000

No summary available. read more...

My Dividend Growth Portfolio - 38 Holdings, 4 Buys, 3 Sells

via: SeekingAlpha at 2018-08-09 01:22:18:000

What's New? Firstly, apologies for getting this out late but we'll understand why. This edition will take some time to go through. June was a tremendously slow month for the portfolio and July was the polar opposite. Firstly, you may have noticed that the number of holdings significantly d… read more...

My Dividend Growth Portfolio - 38 Holdings, 4 Buys, 3 Sells

via: SeekingAlpha at 2018-08-09 01:22:18:000

What's New? Firstly, apologies for getting this out late but we'll understand why. This edition will take some time to go through. June was a tremendously slow month for the portfolio and July was the polar opposite. Firstly, you may have noticed that the number of holdings significantly d… read more...

My Dividend Growth Portfolio - 38 Holdings, 4 Buys, 3 Sells

via: SeekingAlpha at 2018-08-09 01:22:18:000

What's New? Firstly, apologies for getting this out late but we'll understand why. This edition will take some time to go through. June was a tremendously slow month for the portfolio and July was the polar opposite. Firstly, you may have noticed that the number of holdings significantly d… read more...

My Dividend Growth Portfolio - 38 Holdings, 4 Buys, 3 Sells

via: SeekingAlpha at 2018-08-09 01:22:18:000

What's New? Firstly, apologies for getting this out late but we'll understand why. This edition will take some time to go through. June was a tremendously slow month for the portfolio and July was the polar opposite. Firstly, you may have noticed that the number of holdings significantly d… read more...

Abbott Expands its Directional Deep Brain Stimulation Therapy by Offering New MR-Conditional Labeling

via: PR Newswire at 2018-08-02 09:00:00:000

ABBOTT PARK, Ill., Aug. 2, 2018 /PRNewswire/ --Parkinson's disease and essential tremor patients can now benefit from upgraded functionality with Abbott's Infinity DBS system . Abbott (NYSE: ABT)today announced U.S. Food and Drug Administration (FDA) approval for an ov… read more...

Abbott Expands its Directional Deep Brain Stimulation Therapy by Offering New MR-Conditional Labeling

via: PR Newswire at 2018-08-02 09:00:00:000

ABBOTT PARK, Ill., Aug. 2, 2018 /PRNewswire/ --Parkinson's disease and essential tremor patients can now benefit from upgraded functionality with Abbott's Infinity DBS system . Abbott (NYSE: ABT)today announced U.S. Food and Drug Administration (FDA) approval for an ov… read more...

Abbott Expands its Directional Deep Brain Stimulation Therapy by Offering New MR-Conditional Labeling

via: PR Newswire at 2018-08-02 09:00:00:000

ABBOTT PARK, Ill., Aug. 2, 2018 /PRNewswire/ --Parkinson's disease and essential tremor patients can now benefit from upgraded functionality with Abbott's Infinity DBS system . Abbott (NYSE: ABT)today announced U.S. Food and Drug Administration (FDA) approval for an ov… read more...

Meet The 'Safer' 35 Healthcare High Yield WallStars For July

via: SeekingAlpha at 2018-08-01 20:18:44:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.75% to 22.98% Gains To July 2019 Three of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for th… read more...

Meet The 'Safer' 35 Healthcare High Yield WallStars For July

via: SeekingAlpha at 2018-08-01 20:18:44:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.75% to 22.98% Gains To July 2019 Three of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for th… read more...

Meet The 'Safer' 35 Healthcare High Yield WallStars For July

via: SeekingAlpha at 2018-08-01 20:18:44:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.75% to 22.98% Gains To July 2019 Three of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for th… read more...

Nemaura Medical up 21%

via: SeekingAlpha at 2018-08-01 12:40:24:000

Thinly traded Nemaura Medical ( NMRD +20.8% ) is up on more than a 4x surge in volume, albeit on turnover of only 102K shares. The stock is trying to break out of long-term downtrend that began in late January. More news on: Nemaura Medical, Inc., Abbott Laboratories, DexCom, Inc., Healt… read more...

Buy Idexx Laboratories - Cramer's Lightning Round (7/31/18)

via: SeekingAlpha at 2018-08-01 07:12:04:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, July 31. Bullish Calls IDEXX Laboratories (IDXX): Hold on to it, as it's one of the best-acting stocks. The companies for anything genetic, anything biological, even if it is dogs and cats, are do… read more...

Wall Street Favorite Healthcare Equities For July Topped By CVS Health

via: SeekingAlpha at 2018-08-01 02:27:38:000

Actionable Conclusions (1-10): Analysts Projected 12.6% To 28.5% Net Gains For Top Ten Healthcare WallStars By July 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (The… read more...

Cramer's lightning round: The case for buying the best-of-breed stock of UnitedHealth

via: CNBC at 2018-07-31 18:53:00:000

No summary available. read more...

U.S. healthcare spending nearing 20% of GDP

via: SeekingAlpha at 2018-07-31 11:25:57:000

The WSJ reports that healthcare spending in the U.S. will soon reach 20% of GDP, a significantly higher proportion than any other major economy. The key cost driver has been price hikes, not increased demand. Since 1960, the CPI has risen ~700% while medical costs have risen 2,000%. Since … read more...

Ra Medical Systems Aims For $86 Million IPO

via: SeekingAlpha at 2018-07-30 14:58:24:000

Quick Take Ra Medical Systems ( RMED ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm provides laser therapies for a variety of dermatology and vascular diseases through the use of its proprietary products. RM… read more...

Netflix re-releases documentary critical of medical device industry

via: SeekingAlpha at 2018-07-30 09:25:08:000

Medical device makers may experience some mild pressure today on the heels of the re-release by Netflix of " The Bleeding Edge ," a documentary critical of the device industry. Specific products highlighted are Bayer's ( OTCPK:BAYRY ) Essure contraceptive device and Intuitive Surgical's (NAS… read more...

Abbott's FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved in U.S.

via: PR Newswire at 2018-07-27 13:00:00:000

ABBOTT PARK, Ill., July 27, 2018 /PRNewswire/ --Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with… read more...

Abbott's FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved in U.S.

via: PR Newswire at 2018-07-27 13:00:00:000

ABBOTT PARK, Ill., July 27, 2018 /PRNewswire/ --Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with… read more...

Abbott's FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved in U.S.

via: PR Newswire at 2018-07-27 13:00:00:000

ABBOTT PARK, Ill., July 27, 2018 /PRNewswire/ --Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with… read more...

Med tech stocks mired in the red following Edwards, Mettler-Toledo results

via: SeekingAlpha at 2018-07-27 11:46:00:000

Medical device and equipment makers show relative weakness after large-cap peers Edwards Lifesciences ( EW -9.3% ) and Mettler-Toledo ( MTD -3.5% ) reported Q2 results ( I , II ) that disappointed investors. More news on: Edwards Lifesciences Corp, Mettler Toledo International Inc., A… read more...

Med tech stocks mired in the red following Edwards, Mettler-Toledo results

via: SeekingAlpha at 2018-07-27 11:46:00:000

Medical device and equipment makers show relative weakness after large-cap peers Edwards Lifesciences ( EW -9.3% ) and Mettler-Toledo ( MTD -3.5% ) reported Q2 results ( I , II ) that disappointed investors. More news on: Edwards Lifesciences Corp, Mettler Toledo International Inc., A… read more...

Med tech stocks mired in the red following Edwards, Mettler-Toledo results

via: SeekingAlpha at 2018-07-27 11:46:00:000

Medical device and equipment makers show relative weakness after large-cap peers Edwards Lifesciences ( EW -9.3% ) and Mettler-Toledo ( MTD -3.5% ) reported Q2 results ( I , II ) that disappointed investors. More news on: Edwards Lifesciences Corp, Mettler Toledo International Inc., A… read more...

Abbott Begins U.S. Pivotal Trial for the Tendyne Mitral Valve Replacement System to Treat Patients with Heart Valve Disease

via: PR Newswire at 2018-07-26 09:00:00:000

ABBOTT PARK, Ill., July 26, 2018 /PRNewswire/ --Abbott (NYSE: ABT) today announced it has initiated a pivotal clinical study in the U.S. of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of mitral regurgitation. The trial will evaluate the safety a… read more...

Baby DivHut Dividend Income Portfolio Update Q2 2018

via: SeekingAlpha at 2018-07-26 08:05:47:000

Every quarter, I like to review baby DivHut's portfolio and dividend income. With the second quarter of 2018 already in the books, it's time to see how his portfolio has fared. Generally speaking, there is not much change in his portfolio on a month-to-month basis, as fresh capital is not alwa… read more...

Bionano Genomics Proposes Terms For IPO

via: SeekingAlpha at 2018-07-25 21:20:41:000

Quick Take Bionano Genomics ( BNGO ) intends to raise gross proceeds of $30 million from a U.S. IPO, according to an S-1/A registration statement . The firm develops analytic platforms and nanoscale imaging products to analyze DNA. BNGO is growing revenues quickly but is burning cash … read more...

Trump/Juncker In Trade Talks (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-07-25 07:37:39:000

Today's top stories: Trump/Juncker in trade talks; EU reciprocal tariff threat; and Sergio Marchionne passes away. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find all Seeking Alpha Podcasts here )… read more...

Wall Street Breakfast: Key Talks On U.S.-EU Trade

via: SeekingAlpha at 2018-07-25 07:01:49:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). President Trump will sit down with European Commission President Jean-Claude Juncker today to discuss trade, includ… read more...

House repeals tax on medical devices

via: SeekingAlpha at 2018-07-25 05:38:01:000

In a show of bipartisan support, the U.S. House has voted to repeal a 2.3% excise tax on medical devices, which applies to products such as pacemakers and artificial joints, not items directly sold to consumers. More news on: Johnson & Johnson, Medtronic plc, Baxter International Inc… read more...

ViewRay Appoints Scott Drake as President, Chief Executive Officer and a Member of the Board of Directors, Shar Matin as Chief Operating Officer, and D. Keith Grossman as a Member of the Board of Directors

via: PR Newswire at 2018-07-24 16:30:00:000

CLEVELAND , July 24, 2018 /PRNewswire/ --ViewRay, Inc. (Nasdaq: VRAY), maker of the market-leading MRI-guided radiation therapy system,announced today the appointment of medical device industry veterans Scott Drake as its President and Chief Executive Officer and Shar Matin… read more...

Abbot: A "Forever" Stock, But Wait For A Better Entry

via: SeekingAlpha at 2018-07-24 14:07:01:000

Much to my surprise Abbot Laboratories ( ABT ) has only been covered in seven articles so far this year (!). This is surprising to me, considering its good track record both in terms of total returns and dividend growth. ABT has outperformed the S&P 500 by a wide margin over the last 50 ye… read more...

Be On Your Guard - Cramer's Mad Money (7/23/18)

via: SeekingAlpha at 2018-07-24 07:38:31:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday , July 23. The earnings season has kicked in and it has "been more good and little bad." The economic trade policy and tariffs have kept an upper lid on the market and tensions between the US, Canad… read more...

Life Sciences Performing Well For Danaher

via: SeekingAlpha at 2018-07-24 07:00:00:000

Danaher ( DHR ) continues to show why its one of the more highly-regarded conglomerates; second quarter revenue and margin leverage will most likely be on the good side of average in what is shaping up as a pretty good quarter for multi-industrials. In particular, Danahers … read more...

Cramer Remix: Alphabet has broken this troubling trend after reporting earnings

via: CNBC at 2018-07-23 18:59:00:000

No summary available. read more...

Sonar Might Be The Future

via: SeekingAlpha at 2018-07-23 08:15:13:000

In previous articles, I mapped Verilys ( GOOG )( GOOGL ) main projects and detailed why ( DXCM ) was probably the best parallel trade for Verily . A lot has happened since then. The G6 was approved by the FDA and launched way ahead of schedule, Dexcom beat the Q1 earnings, and the sto… read more...

The Passive DGI Core Portfolio: Midyear Review

via: SeekingAlpha at 2018-07-22 09:00:00:000

DGI generally means that you invest in a set of dividend-paying stocks that grow their dividend payout year after year. If you are still in the accumulation phase, reinvest (drip) the dividends, which results in more shares and higher future income. With each passing year, this growth of divid… read more...

Stocks To Watch: FANGs Out In Tech

via: SeekingAlpha at 2018-07-21 08:59:33:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. There's no hiding this week if you're an investor in the tech sector, with heavywei… read more...

If AbbVie Is A Buy, What About Abbott?

via: SeekingAlpha at 2018-07-20 16:28:29:000

After spinning off its researched-based activities into AbbVie ( ABBV ) a few years ago, Abbott Laboratories ( ABT ) has concentrated its focus on various medical devices, nutritional products, and branded generic medicine distributions. Strong from major acquisitions in 2014 and 2017 (Notably… read more...

Is This Dividend Aristocrat A Buy After 17% Revenue And EPS Growth?

via: SeekingAlpha at 2018-07-20 10:46:38:000

Abbott Laboratories ( ABT ) is one of the most recession-resistant companies around. Remarkably, the company managed to grow its dividend each year of the 2007-2009 financial crisis. Abbott Laboratories is also very shareholder-friendly. In fact, the company has increased its dividend for 46… read more...

Beauty Lies In The Eye Of The Investor - Cramer's Mad Money (7/19/18)

via: SeekingAlpha at 2018-07-20 07:34:23:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , July 19. "Beauty lies in the eye of the investor," said Cramer after seeing the Thursday's session where the market either loves a stock or hates it. Case in point is the fintech group which is … read more...

My Dividend Growth Portfolio - Q2 2018 Summary

via: SeekingAlpha at 2018-07-19 19:20:37:000

Introduction It's time to summarize another quarter. This quarter came after a mediocre quarter for me. The first month was a direct continuation of the first quarter. My portfolio suffered from negative returns while the other two months made up for it. The total return in Q2 was 2.2%, whic… read more...

Amazon Tops $900 Billion In Market Value (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-07-19 07:35:53:000

Today's top stories: Amazon tops $900 billion in market value; Brexit negotiations in Brussels today; and the Justice Department wants expedited appeal of AT&T/Time Warner merger. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the fol… read more...

Wall Street Breakfast: Race To $1T Market Cap

via: SeekingAlpha at 2018-07-19 07:01:01:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Amazon reached a $900B market value for the first time on Wednesday, nipping at Apple's (AAPL) heels as Wall Street… read more...

Should You Buy Abbott Laboratories After Its Recent Quarter?

via: SeekingAlpha at 2018-07-18 20:38:52:000

Abbott Laboratories ( ABT ) came out strong when it released its fiscal 2018 Q2 earnings on Wednesday morning. The company topped Wall Street estimates for revenues and earnings, while raising full year guidance in the process. The news has pushed the stock to 52 week highs. While I typically … read more...

Abbott Laboratories (ABT) CEO Miles White on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-18 17:17:07:000

Abbott Laboratories (ABT) Q2 2018 Results Earnings Conference Call July 20, 2018, 9:00 am ET Executives Scott Leinenweber - Vice President, Investor Relations Miles White - Chairman, Chief Executive Officer Brian Yoor - Executive Vice President, Finance, Chief Financial Officer … read more...

DXCM: A Leader In The Shift From Prick To Click

via: SeekingAlpha at 2018-07-18 11:43:31:000

Investment Thesis Dexcom ( DXCM ) is focused on pioneering technologies for the continuous monitoring of glucose in people with diabetes. The healthcare industry has adopted technology and connectivity to provide patients with a more comprehensive ecosystem for managing diabetes. Within th… read more...

Abbott Laboratories 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-18 09:01:34:000

The following slide deck was published by Abbott Laboratories in conjunction with their 2018 Q2 earnings Read more … read more...

Abbott Laboratories Q2 top line up 17%; non-gaap EPS up 18%; shares up 2% premarket

via: SeekingAlpha at 2018-07-18 08:10:27:000

Abbott Laboratories ( ABT ) Q2 results : Revenues: $7,767M (+17.0%); Nutrition: $1,858M (+7.3%); Diagnostics: $1,873M (+47.2%); Established Pharmaceuticals: $1,129M (+10.5%); Medical Devices: $2,891M (+11.3%). More news on: Abbott Laboratories, Healthcare stocks news, Earnings news and co… read more...

Abbott Laboratories beats by $0.02, beats on revenue

via: SeekingAlpha at 2018-07-18 07:46:24:000

Abbott Laboratories (NYSE: ABT ): Q2 EPS of $0.73 beats by $0.02 . More news on: Abbott Laboratories, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Abbott Reports Second-Quarter 2018 Results

via: PR Newswire at 2018-07-18 07:45:00:000

ABBOTT PARK, Ill., July 18, 2018 /PRNewswire/ --Abbott (NYSE: ABT)today announced financial results for the second quarter ended June 30, 2018 . Second-quarter worldwide sales of $7.8 billion increased 17.0 percent on a reported basis and 8.0 percent on an organic* basis… read more...

Stocks rise as Morgan Stanley and CSX surge on earnings

via: CNBC at 2018-07-18 05:17:00:000

No summary available. read more...

Notable earnings before Wednesday's open

via: SeekingAlpha at 2018-07-17 17:30:27:000

ABT , ASML , ERIC , GWW , MS , MTB , MTG , NTRS , NVS , TXT , USB For Seeking Alpha's full earnings season calendar, click here . More news on: Abbott Laboratories, ASML Holding N.V., LM Ericsson Telephone Company, Earnings news and commentary, , read more...

Buying Dividend Growth Stocks Without Looking - More Than 3 Years Later.

via: SeekingAlpha at 2018-07-17 09:44:08:000

In early 2015 I purchased 15 of the largest (capitalization) Dividend Achievers ( VIG ). The Dividend Achievers Index holds larger cap companies that have increased their dividends each year for 15 years or more; those companies also have to pass proprietary dividend health screens. Of course … read more...

Boston Scientific Is A Solid Buy Opportunity In 2018

via: SeekingAlpha at 2018-07-17 09:34:26:000

Lately, Boston Scientific ( BSX ) seems to be in the news for all the right reasons. While the recent news of acquisition of the company by Stryker (SYK) proved to be a rumour, other news updates for the company about its clinical trials, acquisition strategy, restructuring initiatives, and … read more...

Aquestive Therapeutics Readies $60 Million IPO

via: SeekingAlpha at 2018-07-16 11:42:33:000

Quick Take Aquestive Therapeutics ( AQST ) intends to raise $60 million in an IPO of its common stock, according to an amended registration statement . The company is advancing a pipeline of treatment candidates for central nervous system disorders. AQST is using its manufacturing pro… read more...

Trump and Putin are the main event, but there's a lot to move markets in the week ahead

via: CNBC at 2018-07-13 17:52:00:000

No summary available. read more...

Trump and Putin are the main event, but there's a lot to move markets in the week ahead

via: CNBC at 2018-07-13 17:52:00:000

No summary available. read more...

Trump and Putin are the main event, but there's a lot to move markets in the week ahead

via: CNBC at 2018-07-13 17:52:00:000

No summary available. read more...

March To Freedom Fund Mid-Year Review

via: SeekingAlpha at 2018-07-13 12:48:30:000

It has been a long time since Ive updated how the dividend growth portfolio of my wife and I has performed. Apparently, one-year-old boys have two speeds: fast and very fast. I havent had much time to write updates because I spend most of my time chasing the Lil Dividend Bro ar… read more...

March To Freedom Fund Mid-Year Review

via: SeekingAlpha at 2018-07-13 12:48:30:000

It has been a long time since Ive updated how the dividend growth portfolio of my wife and I has performed. Apparently, one-year-old boys have two speeds: fast and very fast. I havent had much time to write updates because I spend most of my time chasing the Lil Dividend Bro ar… read more...

March To Freedom Fund Mid-Year Review

via: SeekingAlpha at 2018-07-13 12:48:30:000

It has been a long time since Ive updated how the dividend growth portfolio of my wife and I has performed. Apparently, one-year-old boys have two speeds: fast and very fast. I havent had much time to write updates because I spend most of my time chasing the Lil Dividend Bro ar… read more...

Constellation Pharmaceuticals Readies $80 Million IPO Plans

via: SeekingAlpha at 2018-07-12 14:32:28:000

Quick Take Constellation Pharmaceuticals ( CNST ) intends to raise gross proceeds of $80 million from a U.S. IPO, according to an S-1/A registration statement . The firm is a clinical-stage biopharmaceutical company which uses epigenetics, a regulatory system that controls gene expres… read more...

Abbott Receives FDA Approval for Next-Generation MitraClip® Device to Treat People with Leaky Heart Valves

via: PR Newswire at 2018-07-12 09:00:00:000

- Innovations designed to allow doctors to treat more types of cases and anatomies - MitraClip is the gold-standard minimally invasive alternative to open-heart surgery for people needing mitral valve repair - Mitral regurgitation, the most common heart valve disease, affects one i… read more...

Fix Your Roof While The Sun Is Shining: The Dividend Aristocrats Are (Sorta) On Sale

via: SeekingAlpha at 2018-07-11 01:51:05:000

A large number of articles on Seeking Alpha are dedicated to dividend growth investing, and one finds no shortage of articles exhorting investors to consider the Dividend Aristocrats. To Seeking Alpha readers, these stocks need no introduction, but as regular contributor Ploutos reminds us… read more...

Replimune Readies $100 Million U.S. IPO

via: SeekingAlpha at 2018-07-10 15:35:28:000

Quick Take Replimune Group ( REPL ) intends to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1/A registration statement . The firm pioneered the first FDA-approved oncolytic immunotherapy -- a neoantigen vaccine specific for patients tumors. This is a… read more...

Danger Zone: Investors Who Don't Insist On Fiduciary Duties

via: SeekingAlpha at 2018-07-10 09:39:18:000

The DOL fiduciary really made the discussion of fiduciary for consumers mainstream. You cant un-ring that bell. - Michael Kitces, Interview with Investment News , June 2, 2018 If you strike me down, I shall become more powerful than you can possibl… read more...

My 44 Holding Dividend Growth Portfolio Update

via: SeekingAlpha at 2018-07-06 09:43:08:000

What's New? June was a particularly busy month for me; birthdays, graduations, Father's Day, vacations, the list is seemingly endless! This is all on top of the typical daily responsibilities of work, running a business, family life and running a household. With all of these daily demands,… read more...

My 44 Holding Dividend Growth Portfolio Update

via: SeekingAlpha at 2018-07-06 09:43:08:000

What's New? June was a particularly busy month for me; birthdays, graduations, Father's Day, vacations, the list is seemingly endless! This is all on top of the typical daily responsibilities of work, running a business, family life and running a household. With all of these daily demands,… read more...

My 44 Holding Dividend Growth Portfolio Update

via: SeekingAlpha at 2018-07-06 09:43:08:000

What's New? June was a particularly busy month for me; birthdays, graduations, Father's Day, vacations, the list is seemingly endless! This is all on top of the typical daily responsibilities of work, running a business, family life and running a household. With all of these daily demands,… read more...

My 44 Holding Dividend Growth Portfolio Update

via: SeekingAlpha at 2018-07-06 09:43:08:000

What's New? June was a particularly busy month for me; birthdays, graduations, Father's Day, vacations, the list is seemingly endless! This is all on top of the typical daily responsibilities of work, running a business, family life and running a household. With all of these daily demands,… read more...

Abbott Labs And Abbvie - 5 Years Later

via: SeekingAlpha at 2018-07-02 08:55:52:000

At the start of 2013, Abbott Laboratories ( ABT ) spun off its branded pharmaceutical business, which has traded since then as Abbvie Inc. ( ABBV ). Prior to the split, Abbott Laboratories was a massively diversified healthcare firm with operations in diagnostics, medical devices, nutrition an… read more...

Abbott Labs And Abbvie - 5 Years Later

via: SeekingAlpha at 2018-07-02 08:55:52:000

At the start of 2013, Abbott Laboratories ( ABT ) spun off its branded pharmaceutical business, which has traded since then as Abbvie Inc. ( ABBV ). Prior to the split, Abbott Laboratories was a massively diversified healthcare firm with operations in diagnostics, medical devices, nutrition an… read more...

Abbott Labs And Abbvie - 5 Years Later

via: SeekingAlpha at 2018-07-02 08:55:52:000

At the start of 2013, Abbott Laboratories ( ABT ) spun off its branded pharmaceutical business, which has traded since then as Abbvie Inc. ( ABBV ). Prior to the split, Abbott Laboratories was a massively diversified healthcare firm with operations in diagnostics, medical devices, nutrition an… read more...

Medical device makers ISRG, BSX, ABT started with bullish view at Bernstein

via: SeekingAlpha at 2018-06-27 19:07:03:000

More gains are ahead for medical device companies, even though the SPDR S&P Health Care Equipment ETF (NYSEARCA: XHE ) is up 21.5%YTD, according to Bernstein analyst Lee Hambright, who argues that innovation is "alive and well" in medical technology, which is reinvigorating grow… read more...

Medical device makers ISRG, BSX, ABT started with bullish view at Bernstein

via: SeekingAlpha at 2018-06-27 19:07:03:000

More gains are ahead for medical device companies, even though the SPDR S&P Health Care Equipment ETF (NYSEARCA: XHE ) is up 21.5%YTD, according to Bernstein analyst Lee Hambright, who argues that innovation is "alive and well" in medical technology, which is reinvigorating grow… read more...

Medical device makers ISRG, BSX, ABT started with bullish view at Bernstein

via: SeekingAlpha at 2018-06-27 19:07:03:000

More gains are ahead for medical device companies, even though the SPDR S&P Health Care Equipment ETF (NYSEARCA: XHE ) is up 21.5%YTD, according to Bernstein analyst Lee Hambright, who argues that innovation is "alive and well" in medical technology, which is reinvigorating grow… read more...

Stocks making the biggest moves in the premarket: CAG, PF, GIS, TEVA, WWE & more

via: CNBC at 2018-06-27 07:42:00:000

No summary available. read more...

Stocks making the biggest moves in the premarket: CAG, PF, GIS, TEVA, WWE & more

via: CNBC at 2018-06-27 07:42:00:000

No summary available. read more...

Stocks making the biggest moves in the premarket: CAG, PF, GIS, TEVA, WWE & more

via: CNBC at 2018-06-27 07:42:00:000

No summary available. read more...

Here Are 43 Of 84 'Safer' Healthcare High Yield Dividend Equities For June

via: SeekingAlpha at 2018-06-26 22:51:03:000

Actionable Conclusions (1-10): Brokers Estimated Top 10 High Yield Healthcare "Safer" Dividend Stocks to Net 9% to 22.98% Gains To June 2019 Five of ten top "safer" dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top 10 gainers for the comin… read more...

Here Are 43 Of 84 'Safer' Healthcare High Yield Dividend Equities For June

via: SeekingAlpha at 2018-06-26 22:51:03:000

Actionable Conclusions (1-10): Brokers Estimated Top 10 High Yield Healthcare "Safer" Dividend Stocks to Net 9% to 22.98% Gains To June 2019 Five of ten top "safer" dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top 10 gainers for the comin… read more...

Here Are 43 Of 84 'Safer' Healthcare High Yield Dividend Equities For June

via: SeekingAlpha at 2018-06-26 22:51:03:000

Actionable Conclusions (1-10): Brokers Estimated Top 10 High Yield Healthcare "Safer" Dividend Stocks to Net 9% to 22.98% Gains To June 2019 Five of ten top "safer" dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top 10 gainers for the comin… read more...

Abbott Announces Freedom 2 Save Program for Employees to Address Student Debt

via: PR Newswire at 2018-06-26 07:00:00:000

ABBOTT PARK, Ill., June 26, 2018 /PRNewswire/ -- Historic levels of student debt have forced many people to choose between saving for their futures and paying off school loans. Abbott (NYSE: ABT) today announced a groundbreaking program that addresses the student debt crisis and changes th… read more...

Top 5 Healthcare Dividend Stocks - A Must To Build A Core Portfolio

via: SeekingAlpha at 2018-06-26 06:49:39:000

Healthcare can be a profitable sector to have in your portfolio. Any dividend growth investor should consider having at least one healthcare dividend stock. As a market, the healthcare industry is highly regulated and not easy to get into, but yet, new research and findings continue to off… read more...

New Late-Breaking Data at ADA Underscore Significant Benefits of Abbott's FreeStyle Libre System for People Living with Diabetes

via: PR Newswire at 2018-06-25 09:00:00:000

ORLANDO, Fla. , June 25, 2018 /PRNewswire/ --Abbott today announced results from multiple new clinical and real-world studies that provide a comprehensive look at the global use of the FreeStyle Libre system, the company's revolutionary continuous glucose monitor (CGM), and its impa… read more...

FDA OKs Tandem's t:slim X2 insulin pump with hypoglycemia management feature; shars up 1% after hours

via: SeekingAlpha at 2018-06-21 16:21:37:000

Tandem Diabetes Care (NASDAQ: TNDM ) is up 1% after hours on light volume on the heels of the FDA's approval of its t:slim X2 Insulin Pump with Basal-IQ, a predictive low glucose suspend feature aimed at reducing the frequency and duration of hypoglycemic (low blood sugar) even… read more...

FDA OKs Tandem's t:slim X2 insulin pump with hypoglycemia management feature; shars up 1% after hours

via: SeekingAlpha at 2018-06-21 16:21:37:000

Tandem Diabetes Care (NASDAQ: TNDM ) is up 1% after hours on light volume on the heels of the FDA's approval of its t:slim X2 Insulin Pump with Basal-IQ, a predictive low glucose suspend feature aimed at reducing the frequency and duration of hypoglycemic (low blood sugar) even… read more...

FDA OKs Senseonics' Eversense CGM device; shares up 1%

via: SeekingAlpha at 2018-06-21 15:25:05:000

The FDA approves Senseonics Holdings' ( SENS +1.2% ) Eversense Continuous Glucose Monitoring (CGM)System. The device features an implantable sensor that lasts up to 90 days. More news on: Senseonics Holdings, Tandem Diabetes Care, Inc., DexCom, Inc., Healthcare stocks news, Sto… read more...

FDA OKs Senseonics' Eversense CGM device; shares up 1%

via: SeekingAlpha at 2018-06-21 15:25:05:000

The FDA approves Senseonics Holdings' ( SENS +1.2% ) Eversense Continuous Glucose Monitoring (CGM)System. The device features an implantable sensor that lasts up to 90 days. More news on: Senseonics Holdings, Tandem Diabetes Care, Inc., DexCom, Inc., Healthcare stocks news, Sto… read more...

Abbott Hosts Conference Call for Second-Quarter Earnings

via: PR Newswire at 2018-06-20 09:00:00:000

ABBOTT PARK, Ill., June 20, 2018 /PRNewswire/ --Abbott (NYSE: ABT)will announce its second-quarter 2018 financial results on Wednesday, July 18, 2018 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a… read more...

Can Fitbit Be Worth $15 By The End Of The Year?

via: SeekingAlpha at 2018-06-18 15:11:22:000

"Citron has done the analysis that NO ONE on Wall Street has taken the time to fully analyze and appreciate. Based on our work and the information that follows, we will explain why $FIT steps all the way up to $15/share in 2018 if not acquired first." With this bold statement , Citron Res… read more...

Can Fitbit Be Worth $15 By The End Of The Year?

via: SeekingAlpha at 2018-06-18 15:11:22:000

"Citron has done the analysis that NO ONE on Wall Street has taken the time to fully analyze and appreciate. Based on our work and the information that follows, we will explain why $FIT steps all the way up to $15/share in 2018 if not acquired first." With this bold statement , Citron Res… read more...

What Does The Rate Hike Mean For Stocks - Cramer's Mad Money (6/13/18)

via: SeekingAlpha at 2018-06-14 07:38:59:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday , June 13. As the Fed has decided to make more rate hikes during the year, buyers became cautious and the market dipped. "Recognize that owning stocks just got harder. Higher rates are not a po… read more...

What Does The Rate Hike Mean For Stocks - Cramer's Mad Money (6/13/18)

via: SeekingAlpha at 2018-06-14 07:38:59:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday , June 13. As the Fed has decided to make more rate hikes during the year, buyers became cautious and the market dipped. "Recognize that owning stocks just got harder. Higher rates are not a po… read more...

What Does The Rate Hike Mean For Stocks - Cramer's Mad Money (6/13/18)

via: SeekingAlpha at 2018-06-14 07:38:59:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday , June 13. As the Fed has decided to make more rate hikes during the year, buyers became cautious and the market dipped. "Recognize that owning stocks just got harder. Higher rates are not a po… read more...

Dividend Income Update: May 2018

via: SeekingAlpha at 2018-06-12 06:10:24:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online, as it only provides further proof that dividend inves… read more...

Dividend Income Update: May 2018

via: SeekingAlpha at 2018-06-12 06:10:24:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online, as it only provides further proof that dividend inves… read more...

Abbott Laboratories declares $0.28 dividend

via: SeekingAlpha at 2018-06-08 11:22:07:000

Abbott Laboratories (NYSE: ABT ) declares $0.28/share quarterly dividend , in line with previous. Forward yield 1.77% Payable Aug. 15; for shareholders of record July 13; ex-div July 12. More news on: Abbott Laboratories, Dividend News, read more...

Abbott Laboratories declares $0.28 dividend

via: SeekingAlpha at 2018-06-08 11:22:07:000

Abbott Laboratories (NYSE: ABT ) declares $0.28/share quarterly dividend , in line with previous. Forward yield 1.77% Payable Aug. 15; for shareholders of record July 13; ex-div July 12. More news on: Abbott Laboratories, Dividend News, read more...

Abbott Laboratories declares $0.28 dividend

via: SeekingAlpha at 2018-06-08 11:22:07:000

Abbott Laboratories (NYSE: ABT ) declares $0.28/share quarterly dividend , in line with previous. Forward yield 1.77% Payable Aug. 15; for shareholders of record July 13; ex-div July 12. More news on: Abbott Laboratories, Dividend News, read more...

Abbott Laboratories declares $0.28 dividend

via: SeekingAlpha at 2018-06-08 11:22:07:000

Abbott Laboratories (NYSE: ABT ) declares $0.28/share quarterly dividend , in line with previous. Forward yield 1.77% Payable Aug. 15; for shareholders of record July 13; ex-div July 12. More news on: Abbott Laboratories, Dividend News, read more...

Abbott Declares 378th Consecutive Quarterly Dividend

via: PR Newswire at 2018-06-08 10:15:00:000

ABBOTT PARK, Ill., June 8, 2018 /PRNewswire/ -- The board of directors of Abbott(NYSE: ABT) today declared a quarterly common dividend of 28 centsper share. This marks the 378 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable&#xA… read more...

Abbott Declares 378th Consecutive Quarterly Dividend

via: PR Newswire at 2018-06-08 10:15:00:000

ABBOTT PARK, Ill., June 8, 2018 /PRNewswire/ -- The board of directors of Abbott(NYSE: ABT) today declared a quarterly common dividend of 28 centsper share. This marks the 378 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable&#xA… read more...

Abbott Declares 378th Consecutive Quarterly Dividend

via: PR Newswire at 2018-06-08 10:15:00:000

ABBOTT PARK, Ill., June 8, 2018 /PRNewswire/ -- The board of directors of Abbott(NYSE: ABT) today declared a quarterly common dividend of 28 centsper share. This marks the 378 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable&#xA… read more...

Abbott Declares 378th Consecutive Quarterly Dividend

via: PR Newswire at 2018-06-08 10:15:00:000

ABBOTT PARK, Ill., June 8, 2018 /PRNewswire/ -- The board of directors of Abbott(NYSE: ABT) today declared a quarterly common dividend of 28 centsper share. This marks the 378 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable&#xA… read more...

For investors looking for a summer fling, one sector could fit the bill

via: CNBC at 2018-06-05 13:22:00:000

No summary available. read more...

For investors looking for a summer fling, one sector could fit the bill

via: CNBC at 2018-06-05 13:22:00:000

No summary available. read more...

For investors looking for a summer fling, one sector could fit the bill

via: CNBC at 2018-06-05 13:22:00:000

No summary available. read more...

My 30 Stock Portfolio +3 Adds

via: SeekingAlpha at 2018-06-05 09:45:40:000

Welcome to my second portfolio update of 2018. The goal of my portfolio is financial freedom. My plan is a combination of dividend growth investing and buying stocks that will beat the market. I call the DGI portion of my portfolio my "dividend machine", I do not DRIP, rather build up cash and… read more...

My 30 Stock Portfolio +3 Adds

via: SeekingAlpha at 2018-06-05 09:45:40:000

Welcome to my second portfolio update of 2018. The goal of my portfolio is financial freedom. My plan is a combination of dividend growth investing and buying stocks that will beat the market. I call the DGI portion of my portfolio my "dividend machine", I do not DRIP, rather build up cash and… read more...

My 30 Stock Portfolio +3 Adds

via: SeekingAlpha at 2018-06-05 09:45:40:000

Welcome to my second portfolio update of 2018. The goal of my portfolio is financial freedom. My plan is a combination of dividend growth investing and buying stocks that will beat the market. I call the DGI portion of my portfolio my "dividend machine", I do not DRIP, rather build up cash and… read more...

My Dividend Growth Portfolio - 45 Holdings, 4 Buys, 1 Sell

via: SeekingAlpha at 2018-06-05 02:05:37:000

What's New? Being an investor primarily focused on generating a growing stream of income, I don't get caught up with the day to day movements of the market as a whole. I don't particularly care what number the S&P is trading at any particular time. I prefer to take the ground up approach… read more...

My Dividend Growth Portfolio - 45 Holdings, 4 Buys, 1 Sell

via: SeekingAlpha at 2018-06-05 02:05:37:000

What's New? Being an investor primarily focused on generating a growing stream of income, I don't get caught up with the day to day movements of the market as a whole. I don't particularly care what number the S&P is trading at any particular time. I prefer to take the ground up approach… read more...

My Dividend Growth Portfolio - 45 Holdings, 4 Buys, 1 Sell

via: SeekingAlpha at 2018-06-05 02:05:37:000

What's New? Being an investor primarily focused on generating a growing stream of income, I don't get caught up with the day to day movements of the market as a whole. I don't particularly care what number the S&P is trading at any particular time. I prefer to take the ground up approach… read more...

Biotech Bio Series #3: Should You Buy The Dip On AbbVie?

via: SeekingAlpha at 2018-06-04 09:27:10:000

This is the third article of the Biotech Bio Series. Big pharma and biotechnology is one of the most exciting sectors in the world today, researching and developing drugs that allow all of us to live longer than ever before. For companies behind this innovation, the approval of one drug may … read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

MeiraGTx Files To Raise $75 Million In IPO

via: SeekingAlpha at 2018-06-01 13:51:39:000

Quick Take MeiraGTx ( MGTX ) intends to raise $75 million from the sale of its ordinary shares, according to an amended S-1/A registration statement . The company is developing a pipeline of treatment candidates for various genetic diseases. MGTX is still in Phase 1 stage and is seeki… read more...

Myriad Genetics To Acquire Counsyl For Women's Reproductive Screening

via: SeekingAlpha at 2018-05-31 12:53:35:000

Quick Take Myriad Genetics ( MYGN ) has announced an agreement to acquire Counsyl for $375 million in a cash and stock transaction. Counsyl has developed as a pioneer in providing women and their families with advanced genetic testing and DNA analysis services. MYGN is acquiring … read more...

Abbott Introduces the Afinion(TM) 2 Analyzer Rapid Test System for Diabetes Management

via: PR Newswire at 2018-05-31 08:00:00:000

ABBOTT PARK, Ill., May 31, 2018 /PRNewswire/ --Abbott (NYSE: ABT)announced today the launch of its Afinion 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with in… read more...

Poplar Forest Capital Quarterly Letter Q1 2018

via: SeekingAlpha at 2018-05-31 00:49:49:000

Read more … read more...

Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease

via: PR Newswire at 2018-05-23 09:00:00:000

ABBOTT PARK, Ill., May 23, 2018 /PRNewswire/ --Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for XIENCE Sierra TM , the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent system. XIENCE … read more...

Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease

via: PR Newswire at 2018-05-23 09:00:00:000

ABBOTT PARK, Ill., May 23, 2018 /PRNewswire/ --Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for XIENCE Sierra TM , the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent system. XIENCE … read more...

Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease

via: PR Newswire at 2018-05-23 09:00:00:000

ABBOTT PARK, Ill., May 23, 2018 /PRNewswire/ --Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for XIENCE Sierra TM , the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent system. XIENCE … read more...

Abbott's Tendyne mitral valve shows positive effect in global study

via: SeekingAlpha at 2018-05-23 08:06:51:000

Preliminary data from a global study evaluating Abbott's (NYSE: ABT ) Tendyne repositionable and fully retrievable mitral replacement valve showed improved patient outcomes. The data were presented at EuroPCR in Paris. More news on: Abbott Laboratories, Healthcare stocks news, Read … read more...

Abbott's Tendyne mitral valve shows positive effect in global study

via: SeekingAlpha at 2018-05-23 08:06:51:000

Preliminary data from a global study evaluating Abbott's (NYSE: ABT ) Tendyne repositionable and fully retrievable mitral replacement valve showed improved patient outcomes. The data were presented at EuroPCR in Paris. More news on: Abbott Laboratories, Healthcare stocks news, Read … read more...

Abbott's Tendyne mitral valve shows positive effect in global study

via: SeekingAlpha at 2018-05-23 08:06:51:000

Preliminary data from a global study evaluating Abbott's (NYSE: ABT ) Tendyne repositionable and fully retrievable mitral replacement valve showed improved patient outcomes. The data were presented at EuroPCR in Paris. More news on: Abbott Laboratories, Healthcare stocks news, Read … read more...

Abbott's Investigational Tendyne(TM) Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Study

via: PR Newswire at 2018-05-23 06:00:00:000

PARIS , May 23, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, the first and only mitral replacement valve that is repositionable and full… read more...

Abbott's Investigational Tendyne(TM) Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Study

via: PR Newswire at 2018-05-23 06:00:00:000

PARIS , May 23, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, the first and only mitral replacement valve that is repositionable and full… read more...

Abbott's Investigational Tendyne(TM) Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Study

via: PR Newswire at 2018-05-23 06:00:00:000

PARIS , May 23, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, the first and only mitral replacement valve that is repositionable and full… read more...

Abbott's stent guide improved outcomes in long-term study

via: SeekingAlpha at 2018-05-22 09:25:31:000

Five-year data from the FAME 2 study assessing Abbott's (NYSE: ABT ) PressureWire, a fractional flow reserve (FFR) diagnostic tool, to better inform stent placement showed improved patient outcomes. The results were presented at EuroPCR in Paris. More news on: Abbott Laboratories, Healt… read more...

Five-Year Study Data Confirm Positive Outcomes for Patients When Abbott Diagnostic Tool Was Used to Guide Heart Stenting Decisions

via: PR Newswire at 2018-05-22 06:20:00:000

PARIS , May 22, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced five-year results from the FAME 2 study, which showed that patients had fewer major adverse cardiac events (MACE) when they received a heart stent guided by Abbott's fractional flow reserve (FFR) diagnostic tool in co… read more...

MeiraGTx Aims For $86 Million U.S. IPO

via: SeekingAlpha at 2018-05-18 11:44:30:000

Quick Take MeiraGTx ( MGTX ) intends to raise $86.25 million from the sale of its common stock in an IPO, according to a registration statement filed with the SEC. The firm is a clinical stage developer of gene therapies focused on diseases of the eye, salivary gland and central nervou… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter

via: PR Newswire at 2018-05-03 09:00:00:000

ABBOTT PARK, Ill., May 3, 2018 /PRNewswire/ -- Abbott (NYSE: ABT)today announced U.S. Food and Drug Administration (FDA) clearance of the Advisor HD Grid Mapping Catheter, Sensor Enabled . Advisor HD Grid employs a new design that allows physicians to see things diff… read more...

Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter

via: PR Newswire at 2018-05-03 09:00:00:000

ABBOTT PARK, Ill., May 3, 2018 /PRNewswire/ -- Abbott (NYSE: ABT)today announced U.S. Food and Drug Administration (FDA) clearance of the Advisor HD Grid Mapping Catheter, Sensor Enabled . Advisor HD Grid employs a new design that allows physicians to see things diff… read more...

My Dividend Growth Portfolio - 42 Holdings, 4 Buys

via: SeekingAlpha at 2018-05-03 05:22:14:000

April was a much busier month than March. On the investing front, we are in the middle of earnings season. Earnings season is the quarterly time of year when investors get that inside snapshot as to how each company is operating. So far it has been quite good which in turn is why I've felt com… read more...

My Dividend Growth Portfolio - 42 Holdings, 4 Buys

via: SeekingAlpha at 2018-05-03 05:22:14:000

April was a much busier month than March. On the investing front, we are in the middle of earnings season. Earnings season is the quarterly time of year when investors get that inside snapshot as to how each company is operating. So far it has been quite good which in turn is why I've felt com… read more...

Abbott's XIENCE Sierra(TM) Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease

via: PR Newswire at 2018-05-02 09:00:00:000

ABBOTT PARK, Ill., May 2, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary st… read more...

Abbott's XIENCE Sierra(TM) Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease

via: PR Newswire at 2018-05-02 09:00:00:000

ABBOTT PARK, Ill., May 2, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary st… read more...

Roche Drifting Without Perception-Changing Data

via: SeekingAlpha at 2018-04-30 15:28:33:000

Once tapped as the future belle of the ball due to its deep pipeline of potential add-on/combo oncology therapies, Roche ( OTCQX:RHHBY ) has continued to lag rivals like Merck ( MRK ) as investors grow more concerned that Roches PD-L1 antibody Tecentriq will have trouble standing o… read more...

This Dividend Aristocrat Just Printed 40%+ EPS Growth - Is It A Buy?

via: SeekingAlpha at 2018-04-27 11:06:34:000

By Nick McCullum At Sure Dividend, we often write about the merits of investing in the Dividend Aristocrats. In order to be a Dividend Aristocrat, a company must: Be in the S&P 500 Meet certain minimum size and liquidity requirements Have 25+ years of consecutive dividend in… read more...

Sanquin Selects Abbott's "Alinity(TM) s" Solution for Blood and Plasma Screening

via: PR Newswire at 2018-04-23 09:00:00:000

LONG-TERM AGREEMENT BETWEEN SANQUIN, A LEADER IN BLOOD SERVICES, AND ABBOTT, A GLOBAL LEADER IN TRANSFUSION MEDICINE,HELPS ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY IN THE NETHERLANDS AMSTERDAM , April 23, 2018 /PRNewswire/ --Sanquin and Abbott (NYSE: ABT)announced … read more...

Sanquin Selects Abbott's "Alinity(TM) s" Solution for Blood and Plasma Screening

via: PR Newswire at 2018-04-23 09:00:00:000

AMSTERDAM , April 23, 2018 /PRNewswire/ --Sanquin and Abbott (NYSE: ABT)announced today that they signed a multiple-year contract for the supply of primary serological equipment and consumables, including Abbott's Alinity s system, for blood and plasma screening. i Th… read more...

The Passive DGI Core Portfolio: Income, Safety, And Growth

via: SeekingAlpha at 2018-04-21 08:38:00:000

The concept of Dividend Growth Investing (or DGI) is simple and rational. DGI generally means that you invest in a set of dividend-paying stocks that grow their dividend payout year after year. If you are still in the accumulation phase, reinvest (drip) the dividends, which results in more sha… read more...

Danaher's Growing Leverage To Life Sciences Improves The Long-Term Outlook

via: SeekingAlpha at 2018-04-20 14:22:35:000

As investors have become a little more concerned that the industrial recovery story has peaked, Danaher s ( DHR ) far larger skew towards health and life sciences has started looking better and better. At the risk of oversimplification, I think the greater skew toward health care/life… read more...

'Safer' Dividend Aristocrats Top Gainers Are Leggett, Procter, Air, Nucor, & Praxair, Per Broker February Targets

via: SeekingAlpha at 2018-02-07 10:41:14:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend Aristocrats Stocks to Net 8.23% to 23.59% Gains To February, 2019 Three of ten top yield "safer" Dividend Aristocrats (tinted in the chart above) were also in the Top ten gainers for the coming year based on analyst 1… read more...

'Safer' Dividend Aristocrats Top Gainers Are Leggett, Procter, Air, Nucor, & Praxair, Per Broker February Targets

via: SeekingAlpha at 2018-02-07 10:41:14:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend Aristocrats Stocks to Net 8.23% to 23.59% Gains To February, 2019 Three of ten top yield "safer" Dividend Aristocrats (tinted in the chart above) were also in the Top ten gainers for the coming year based on analyst 1… read more...

'Safer' Dividend Aristocrats Top Gainers Are Leggett, Procter, Air, Nucor, & Praxair, Per Broker February Targets

via: SeekingAlpha at 2018-02-07 10:41:14:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten 'Safer' Dividend Aristocrats Stocks to Net 8.23% to 23.59% Gains To February, 2019 Three of ten top yield "safer" Dividend Aristocrats (tinted in the chart above) were also in the Top ten gainers for the coming year based on analyst 1… read more...

Abbott's App for FreeStyle® Libre System Now Available in Europe for Both iPhone(TM) and Android(TM)

via: PR Newswire at 2018-02-07 09:00:00:000

ABBOTT PARK, Ill., Feb. 7, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the FreeStyle LibreLink app is now available in Europe for use with compatible smartphones 2 (both iPhone and Android). People with diabetes living in Europe and using the FreeStyle Libre system… read more...

Abbott's App for FreeStyle® Libre System Now Available in Europe for Both iPhone(TM) and Android(TM)

via: PR Newswire at 2018-02-07 09:00:00:000

ABBOTT PARK, Ill., Feb. 7, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the FreeStyle LibreLink app is now available in Europe for use with compatible smartphones 2 (both iPhone and Android). People with diabetes living in Europe and using the FreeStyle Libre system… read more...

Abbott's App for FreeStyle® Libre System Now Available in Europe for Both iPhone(TM) and Android(TM)

via: PR Newswire at 2018-02-07 09:00:00:000

ABBOTT PARK, Ill., Feb. 7, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the FreeStyle LibreLink app is now available in Europe for use with compatible smartphones 2 (both iPhone and Android). People with diabetes living in Europe and using the FreeStyle Libre system… read more...

My Dividend Growth Portfolio - 46 Holdings, 1 Buy, 2 Sells

via: SeekingAlpha at 2018-02-06 10:29:12:000

Welcome to the January 2018 update for my dividend growth portfolio. The year has started off with a big bang as each company analyzes (and some guide) to how the tax plan will change their upcoming 2018 earnings forecasts. Though recently the market has taken a breather, stocks trade at an el… read more...

Dividend Aristocrat Tailor-Made For Overheated Market

via: SeekingAlpha at 2018-02-02 16:10:06:000

Dividend growth investors place great faith in reliable growing dividend streams. Abbott (ABT) stands out on that metric as I will document. Abbott also has another characteristic which I regard as more forward looking. Abbott has an unparalleled clutch of new products. By and large, they are … read more...

Dividend Aristocrat Tailor-Made For Overheated Market

via: SeekingAlpha at 2018-02-02 16:10:06:000

Dividend growth investors place great faith in reliable growing dividend streams. Abbott (ABT) stands out on that metric as I will document. Abbott also has another characteristic which I regard as more forward looking. Abbott has an unparalleled clutch of new products. By and large, they are … read more...

Dividend Aristocrat Tailor-Made For Overheated Market

via: SeekingAlpha at 2018-02-02 16:10:06:000

Dividend growth investors place great faith in reliable growing dividend streams. Abbott (ABT) stands out on that metric as I will document. Abbott also has another characteristic which I regard as more forward looking. Abbott has an unparalleled clutch of new products. By and large, they are … read more...

Dividend Aristocrat Tailor-Made For Overheated Market

via: SeekingAlpha at 2018-02-02 16:10:06:000

Dividend growth investors place great faith in reliable growing dividend streams. Abbott (ABT) stands out on that metric as I will document. Abbott also has another characteristic which I regard as more forward looking. Abbott has an unparalleled clutch of new products. By and large, they are … read more...

Baby DivHut Dividend Income Portfolio Update Q4 2017

via: SeekingAlpha at 2018-02-01 05:33:50:000

Every quarter I like to review baby DivHut's portfolio and dividend income. Generally speaking, there is not much change in his portfolio on a month-to-month basis as fresh capital is not always available to make trades for him. Still, with dividend reinvestments, stock spin-offs and a small… read more...

Baby DivHut Dividend Income Portfolio Update Q4 2017

via: SeekingAlpha at 2018-02-01 05:33:50:000

Every quarter I like to review baby DivHut's portfolio and dividend income. Generally speaking, there is not much change in his portfolio on a month-to-month basis as fresh capital is not always available to make trades for him. Still, with dividend reinvestments, stock spin-offs and a small… read more...

AbbVie With A Blowout Quarter But Should You Still Buy It?

via: SeekingAlpha at 2018-01-31 18:03:56:000

Big biotech AbbVie ( ABBV ) just posted stellar Q4/2017 results beating estimates top- and bottom-line and exciting investors about its bullish guidance pointing to a further acceleration in growth. Source: AbbVie Investor Relations Fueled by its Humira cash cow and spectacular growth in… read more...

AbbVie With A Blowout Quarter But Should You Still Buy It?

via: SeekingAlpha at 2018-01-31 18:03:56:000

Big biotech AbbVie ( ABBV ) just posted stellar Q4/2017 results beating estimates top- and bottom-line and exciting investors about its bullish guidance pointing to a further acceleration in growth. Source: AbbVie Investor Relations Fueled by its Humira cash cow and spectacular growth in… read more...

Embrace The Volatility - Cramer's Mad Money (1/29/18)

via: SeekingAlpha at 2018-01-30 07:38:41:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, January 29. Cramer cautioned investors to embrace upcoming volatility now that the crux of the earnings season is on. With so many stocks due to report earnings, there will be massive ups and downs, winn… read more...

Embrace The Volatility - Cramer's Mad Money (1/29/18)

via: SeekingAlpha at 2018-01-30 07:38:41:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, January 29. Cramer cautioned investors to embrace upcoming volatility now that the crux of the earnings season is on. With so many stocks due to report earnings, there will be massive ups and downs, winn… read more...

Embrace The Volatility - Cramer's Mad Money (1/29/18)

via: SeekingAlpha at 2018-01-30 07:38:41:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, January 29. Cramer cautioned investors to embrace upcoming volatility now that the crux of the earnings season is on. With so many stocks due to report earnings, there will be massive ups and downs, winn… read more...

Fractional Shares And No Fees: How To Save Money By Going Direct

via: SeekingAlpha at 2018-01-29 09:34:09:000

If you're a long-term investor like myself, you probably invest via dollar cost average ((DCA)) into your portfolio monthly or quarterly. And if not, you've at least maybe heard of the strategy. In fact you might be a DCA investor and not even realize it. That's right - if you participate in y… read more...

Fractional Shares And No Fees: How To Save Money By Going Direct

via: SeekingAlpha at 2018-01-29 09:34:09:000

If you're a long-term investor like myself, you probably invest via dollar cost average ((DCA)) into your portfolio monthly or quarterly. And if not, you've at least maybe heard of the strategy. In fact you might be a DCA investor and not even realize it. That's right - if you participate in y… read more...

Fractional Shares And No Fees: How To Save Money By Going Direct

via: SeekingAlpha at 2018-01-29 09:34:09:000

If you're a long-term investor like myself, you probably invest via dollar cost average ((DCA)) into your portfolio monthly or quarterly. And if not, you've at least maybe heard of the strategy. In fact you might be a DCA investor and not even realize it. That's right - if you participate in y… read more...

AbbVie: Too Darn Hot?

via: SeekingAlpha at 2018-01-29 04:46:24:000

Introduction To my surprise, AbbVie ( ABBV ) has turned into a growth stock. As noted next, I began seeing this when the stock was much lower than it is now, and not much has changed. This article addresses matters from the standpoint of an investor wondering about buying ABBV now that i… read more...

AbbVie: Too Darn Hot?

via: SeekingAlpha at 2018-01-29 04:46:24:000

Introduction To my surprise, AbbVie ( ABBV ) has turned into a growth stock. As noted next, I began seeing this when the stock was much lower than it is now, and not much has changed. This article addresses matters from the standpoint of an investor wondering about buying ABBV now that i… read more...

AbbVie: Too Darn Hot?

via: SeekingAlpha at 2018-01-29 04:46:24:000

Introduction To my surprise, AbbVie ( ABBV ) has turned into a growth stock. As noted next, I began seeing this when the stock was much lower than it is now, and not much has changed. This article addresses matters from the standpoint of an investor wondering about buying ABBV now that i… read more...

The Performance Of Every Dividend Aristocrat During The Great Recession

via: SeekingAlpha at 2018-01-28 03:27:18:000

The Dividend Aristocrats - stocks with 25+ years of consecutive dividend increases - are, by definition, quite recession resistant. This is because it takes a strong and durable competitive advantage for a company to increase its dividend each year for more than two consecutive year… read more...

The Performance Of Every Dividend Aristocrat During The Great Recession

via: SeekingAlpha at 2018-01-28 03:27:18:000

The Dividend Aristocrats - stocks with 25+ years of consecutive dividend increases - are, by definition, quite recession resistant. This is because it takes a strong and durable competitive advantage for a company to increase its dividend each year for more than two consecutive year… read more...

The Performance Of Every Dividend Aristocrat During The Great Recession

via: SeekingAlpha at 2018-01-28 03:27:18:000

The Dividend Aristocrats - stocks with 25+ years of consecutive dividend increases - are, by definition, quite recession resistant. This is because it takes a strong and durable competitive advantage for a company to increase its dividend each year for more than two consecutive year… read more...

The Performance Of Every Dividend Aristocrat During The Great Recession

via: SeekingAlpha at 2018-01-28 03:27:18:000

The Dividend Aristocrats - stocks with 25+ years of consecutive dividend increases - are, by definition, quite recession resistant. This is because it takes a strong and durable competitive advantage for a company to increase its dividend each year for more than two consecutive year… read more...

Abbott Laboratories 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-01-25 15:31:49:000

The following slide deck was published by Abbott Laboratories in conjunction with their 2017 Q4 earnings Read more … read more...

Wall Street Breakfast: Major Currencies On The Move

via: SeekingAlpha at 2018-01-25 07:02:41:000

The dollar index stretched overnight losses to plumb 88.89, marking three-year lows, after U.S. Treasury Secretary Steven Mnuchin suggested a weak greenback would be good for the U.S. That's a departure from decades of traditional U.S. policy, though Mnuchin clarified that the U.S…. read more...

Looks Like The Smart Beta Just Got Dumb And Dumber

via: SeekingAlpha at 2018-01-24 15:12:31:000

In March of 2015 I purchased 15 of the largest cap Dividend Achievers ( VIG ). I did no additional financial evaluation other than reading that list. The 15 companies that I added are 3M (NYSE: MMM ), Pepsi (NYSE: PEP ), CVS Health Corporation (NYSE: CVS ), Wal-Mart (NYSE: WMT ), Johnson &… read more...

Abbott Laboratories' (ABT) CEO, Miles White on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-01-24 14:03:06:000

Abbott Laboratories (ABT) Q4 2017 Earnings Conference Call January 24, 2017 9:00 am ET Executives Miles White - Chairman, Chief Executive Officer Brian Yoor - Executive Vice President, Finance, Chief Financial Officer Scott Leinenweber - Vice President, Investor Relations Ana… read more...

This Dividend Aristocrat Rose 4% After Fantastic Earnings; Is It Still A Buy?

via: SeekingAlpha at 2018-01-24 12:23:54:000

Abbott Laboratories ( ABT ) is one of the most stable dividend stocks around. With 46 years of consecutive dividend increases, the company is in elite company. Abbott is a member of the Dividend Aristocrats list , a group of companies with 25+ years of consecutive dividend increases. It isn… read more...

What's That Smell? My Bonds

via: SeekingAlpha at 2018-01-24 11:23:46:000

Off the top, let me state for the record that I am a big fan of bonds. They are a wonderful tool for portfolio diversification and a wonderful asset for risk management. I often refer to them as portfolio "shock absorbers". That's a wonderful analogy (if I say so myself) that allows unsophisti… read more...

Abbott Laboratories Q4 revenues up 42%; non-GAAP EPS up 14%; updates guidance

via: SeekingAlpha at 2018-01-24 08:10:04:000

Abbott Laboratories ( ABT ) Q4 results : Revenues: $7,589M (+42.3%); Nutrition: $1,784M (+42.3%); Diagnostics: $1,906M (+51.7%); Established Pharmaceuticals: $1,145M; Medical Devices: $2,737M (+102.2%). More news on: Abbott Laboratories, Healthcare stocks news, Earnings news and commentar… read more...

Abbott Laboratories beats by $0.01, beats on revenue

via: SeekingAlpha at 2018-01-24 07:47:09:000

Abbott Laboratories (NYSE: ABT ): Q4 EPS of $0.74 beats by $0.01 . More news on: Abbott Laboratories, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Abbott Reports Fourth-Quarter 2017 Results

via: PR Newswire at 2018-01-24 07:45:00:000

ABBOTT PARK, Ill., Jan. 24, 2018 /PRNewswire/ --Abbott (NYSE: ABT)today announced financial results for the fourth quarter ended Dec. 31, 2017 . Fourth-quarter worldwide sales of $7.6 billion increased 42.3 percent on a reported basis and 7.7 percent on a comparable oper… read more...

Notable earnings before Wednesday's open

via: SeekingAlpha at 2018-01-23 17:30:13:000

ABT , APH , AUDC , BHGE , BOKF , CMCSA , CVLT , GD , GE , GWW , ITW , NSC , NTRS , NVS , PB , PGR , RCL , RES , ROK , ROL , SWK , TEL , UMC , UTX For Seeking Alpha's full earnings season calendar, click here . More news on: Abbott Laboratories, Amphenol Corpor… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
2017-10-12 2017-11-15 2017-10-13 2017-09-14 0.265 Dividend income
2017-07-12 2017-08-15 2017-07-14 2017-06-09 0.265 Dividend income Q
2017-04-11 2017-05-15 2017-04-14 2017-02-17 0.265 Dividend income Q
2017-01-11 2017-02-15 2017-01-13 2016-12-09 0.265 Dividend income Q
2016-10-12 2016-11-15 2016-10-14 2016-09-15 0.26 Dividend income Q
2016-07-13 2016-08-15 2016-07-15 2016-06-10 0.26 Dividend income Q
2016-04-13 2016-05-16 2016-04-15 2016-02-19 0.26 Dividend income Q
2016-01-13 2016-02-16 2016-01-15 2015-12-11 0.26 Dividend income Q
2015-10-13 2015-11-15 2015-10-15 2015-09-17 0.24 Dividend income Q
2015-07-13 2015-08-15 2015-07-15 2015-06-12 0.24 Dividend income Q
2015-04-13 2015-05-15 2015-04-15 2015-02-20 0.24 Dividend income Q
2015-01-13 2015-02-13 2015-01-15 2014-12-12 0.24 Dividend income Q
2014-10-10 2014-11-15 2014-10-15 2014-09-11 0.22 Dividend income Q
2014-07-11 2014-08-15 2014-07-15 2014-06-13 0.22 Dividend income Q
2014-04-11 2014-05-15 2014-04-15 2014-02-21 0.22 Dividend income Q
2014-01-13 2014-02-15 2014-01-15 2013-10-16 0.22 Dividend income Q
2013-10-10 2013-11-15 2013-10-15 2013-09-12 0.14 Dividend income Q
2013-07-11 2013-08-15 2013-07-15 2013-06-14 0.14 Dividend income Q
2013-04-11 2013-05-15 2013-04-15 2013-02-15 0.14 Dividend income Q
2013-01-11 2013-02-15 2013-01-15 2012-12-14 0.14 Dividend income Q
2013-01-02 2013-01-01 2012-12-12 2012-11-28 Stock dividend
2018-01-11 2018-02-15 2018-01-12 2017-12-15 0.28 FI Dividend income
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2013-01-02 0.4798 10000.0 4798.0
Data provided for free by IEX